Page last updated: 2024-11-06

mefloquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mefloquine is an antimalarial drug that was synthesized in the 1970s. It is effective against Plasmodium falciparum, a parasite that causes malaria. Mefloquine is typically used for the prevention and treatment of malaria, but it can also be used to treat other conditions, such as certain types of epilepsy. Mefloquine works by interfering with the parasite's ability to reproduce. The mechanism of action involves inhibiting the parasite's heme detoxification pathway, which is essential for its survival. Mefloquine is typically taken once a week as a preventive measure or for short-term treatment. It is generally safe and well-tolerated, but side effects can occur. These can include nausea, vomiting, dizziness, and headaches. In rare cases, more serious side effects can occur, such as seizures, psychosis, and depression. Mefloquine is not recommended for pregnant women or breastfeeding mothers. Research on mefloquine continues to focus on understanding its effectiveness, safety, and potential for resistance development in malaria parasites. Studies are also ongoing to explore alternative formulations and delivery methods for mefloquine, aiming to improve patient compliance and minimize side effects.'

(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID40692
CHEMBL ID172
CHEBI ID63687
CHEBI ID63609
SCHEMBL ID21780
MeSH IDM0024162
PubMed CID12986439
SCHEMBL ID8575605
MeSH IDM0024162

Synonyms (93)

Synonym
BIDD:PXR0166
BIDD:GT0596
mephloquine
mefloquina [inn-spanish]
mefloquinum [inn-latin]
(dl-erythro-alpha-2-piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
wr 142490
mefloquine [usan:inn:ban]
hsdb 6853
4-quinolinemethanol, alpha-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphas)-rel-
4-quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (r*,s*)-(+-)-
mefloquin
ro 21-5998
ro 215998
bdbm50151865
(-)-mefloquine
(s)-[2,8-bis(trifluoromethyl)-4-quinolyl]-[(2r)-2-piperidyl]methanol
ro 13-7225
(+)-erythro-4-quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-
(+)-(11s,2'r)-erythro-mefloquine
4-quinolinemethanol, .alpha.-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.s)-
4-quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (r*,s*)-(+/-)-
rti1189-1-1
mefloquine (usan/inn)
D04895
MLS001332559 ,
smr000875233
C07633
NCGC00161831-02
NCGC00161831-01
(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2r)-piperidin-2-yl]methanol
ro-215998
(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol
CHEMBL172 ,
chebi:63687 ,
(s,r)-mefloquine
(s)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((r)-piperidin-2-yl)methanol
NCGC00161831-03
BRD-K40645748-003-08-5
(-)-(11s,2'r)-erythro-mefloquine
4-quinolinemethanol, alpha-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphas)-
51742-87-1
nsc 758233
tml814419r ,
unii-tml814419r
mefloquina
mefloquinum
[(11s,2'r)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
mefloquine [hsdb]
mefloquine [mi]
mefloquine [usan]
4-quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (r*,s*)-(+/-)-
mefloquine [who-dd]
mefloquine [vandf]
mefloquine [inn]
SCHEMBL21780
(s)-[2,8-bis(trifluoromethyl)-4-quinolyl]-[(2r)-2-piperidyl]methanol;hydrochloride
cid_65329
(s)-[2,8-bis(trifluoromethyl)-4-quinolinyl]-[(2r)-2-piperidinyl]methanol;hydrochloride
bdbm79170
DTXSID4037168 ,
mmv000014
Q27084116
147368-41-0
DTXSID101019853
mmv000016
XEEQGYMUWCZPDN-DOMZBBRYSA-N ,
nsc-790109
nsc790109
4-quinolinemethanol, a-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-,(as)-rel-
4-quinolinemethanol, .alpha.-[(2r)-2-piperidinyl]-2,8-bis(trifluoromethyl)-, (.alpha.s)-, rel-
CS-0007927
HY-17437
AKOS040732205
chebi:63609
(dl-erythro-alpha-2-piperidyl-2,8-bis(trifluoromethyl))-4-quinolinemethanol
dtxcid001473959
mefloquinum (latin)
((r*,s*)-2,8-bis(trifluoromethyl)quinolin-4-yl)-(2-piperidyl)methanol
mephaquine
rac--(r)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((2s)-piperidin-2-yl)methanol
mefloquinum (inn-latin)
p01bc02
mefloquina (inn-spanish)
rel-(alphas)-alpha-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
mefloquine
53230-10-7
(s)-[2,8-bis(trifluoromethyl)-4-quinolyl]-(2-piperidyl)methanol
SCHEMBL8575605
4-quinolinemethanol, .alpha.-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.s)-rel-
[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol;hydrochloride
(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
PD052757

Research Excerpts

Effects

ExcerptReferenceRelevance
"Mefloquine has confirmed anti-ZIKV activity."( 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
Araújo, ADS; Barbosa-Lima, G; Bozza, PT; da Silva, ET; de Freitas, CS; de Souza, MVN; Marttorelli, A; Moraes, AM; Neto, JC; Souza, TML; Vieira, YR, 2017
)
1.4

Toxicity

The association between MDR1 C1236T, G2677T, and C3435T single-nucleotide polymorphisms and the occurrence of neuropsychiatric adverse effects was examined in a prospective cohort study. Application of pharmacokinetics permitted definitive treatment with mefloquine in a safe and effective manner.

ExcerptReferenceRelevance
" Given the adverse impact of malaria in pregnancy, these events may be important for at least two reasons: it may be possible to use reported fever illness as a determinant of which women need an antimalarial intervention, and, it is possible that adverse symptoms following the antimalarial intervention may be important determinants of continued adherence to the prevention regimen."( Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.
Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996
)
0.29
" The aim was to examine maternal fever and to evaluate side effects and the frequency of adverse reproductive outcomes for their possible association with malaria or the antimalarial drug regimens."( Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.
Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996
)
0.29
"This longitudinal study of travellers to Africa taking mefloquine (MQ) chemoprophylaxis aimed to quantify and assess non-serious adverse events (AE) occurring during short-term prophylaxis and relate these to concentrations of racemic MQ, its enantiomers and metabolite."( Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance.
Bergqvist, Y; Ericsson, O; Handschin, J; Hellgren, U; Johnson, R; Letz, R; Lobel, H; Mannino, S; Rombo, L; Schlagenhauf, P; Steffen, R; Stürchler, D; Tschopp, A; Vranjes, N, 1996
)
0.29
"To compare the frequency of adverse events, particularly neuropsychiatric effects, from mefloquine and from chloroquine plus proguanil as used for malaria chemoprophylaxis."( Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD, 1996
)
0.29
" Overall, neuropsychiatric adverse events were significantly more common in travellers taking mefloquine."( Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD, 1996
)
0.29
"There is a significant excess of adverse neuropsychiatric events of intermediate degrees of severity associated with the use of mefloquine compared with proguanil plus chloroquine."( Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD, 1996
)
0.29
" Subject to the limitations of a response rate that was smaller than desired and the fact that the study was conducted in fit male military personnel, these results support evidence which indicates that mefloquine is no more toxic than chloroquine-proguanil."( Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial.
Clayton, TC; Croft, AM; World, MJ,
)
0.13
"We had the impression that adverse reactions to standard antimalarial prophylaxis were reported much more often than stated by the package insert and medical drug references; and that side effects adversely affected compliance."( Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis.
de Munter, J; Hoebe, C; Thijs, C, 1997
)
0.3
"We can confirm the reports by users that adverse effects of mefloquine and proguanil are common and, although mostly mild, adversely affect compliance."( Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis.
de Munter, J; Hoebe, C; Thijs, C, 1997
)
0.3
"To evaluate the frequency and type of adverse drug reactions associated to the antimalarial chemoprophylaxis advised to travellers visiting endemic areas."( [Adverse effects associated with antimalarial chemoprophylaxis].
Caparrós, F; Codina, C; Corachán, M; Corominas, N; Gascón, J; Mejías, T; Quintó, L; Ribas, J, 1997
)
0.3
" The adverse drug reactions were reported by the travellers through a questionnaire handed at the consulting room."( [Adverse effects associated with antimalarial chemoprophylaxis].
Caparrós, F; Codina, C; Corachán, M; Corominas, N; Gascón, J; Mejías, T; Quintó, L; Ribas, J, 1997
)
0.3
"4% of the travellers reported adverse drug reactions."( [Adverse effects associated with antimalarial chemoprophylaxis].
Caparrós, F; Codina, C; Corachán, M; Corominas, N; Gascón, J; Mejías, T; Quintó, L; Ribas, J, 1997
)
0.3
"The adverse drug reactions reported agree with the toxicologic profile described in the literature about these drugs."( [Adverse effects associated with antimalarial chemoprophylaxis].
Caparrós, F; Codina, C; Corachán, M; Corominas, N; Gascón, J; Mejías, T; Quintó, L; Ribas, J, 1997
)
0.3
" Differences in rates of adverse outcomes between the three groups were not statistically significant."( Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy.
Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998
)
0.3
" Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group."( Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand.
Canfield, CJ; Chalermarut, K; Hutchinson, DB; Looareesuwan, S; Rattanapong, Y; Wilairatana, P, 1999
)
0.3
" There was no difference in the incidence of possible adverse effects between the two drugs, and no evidence that either derivative caused allergic reactions, neurologic or psychiatric reactions, or cardiovascular or dermatologic toxicity."( Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.
Chongsuphajaisiddhi, T; Kham, A; Luxemburger, C; McGready, R; Nosten, F; Phaipun, L; Price, R; Simpson, J; ter Kuile, F; van Vugt, M; White, NJ, 1999
)
0.3
"Mefloquine is a relatively new antimalarial drug which has been associated with a wide variety of adverse effects, including skin reactions."( Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports.
Black, MM; Croft, AM; Smith, HR, 1999
)
0.3
" The pharmacokinetic data, however, showed that they are of similar profile, except in adverse features and contraindications, and values like their half-life (t1/2) where the long (t1/2) in drugs like sulphadoxine-pyrimethamine endows them with suppressive-cure feature, especially against recrudescent strains."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.3
" Pharmacokinetic profile demonstrates that all these drugs have similar therapeutic effects, but differ in their adverse reactions, contraindications, and half-life."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.3
" However, since introduced in 1985, there have been over 100 reports of severe neurologic and psychiatric adverse effects associated with its use, including acute psychosis, affective disorders, acute confusional states and seizures."( [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].
Minei-Rachmilewitz, T, 1999
)
0.3
" The most commonly reported and possibly related adverse effects following A-L therapy involved the gastro-intestinal (abdominal pain, anorexia, nausea, vomiting, diarrhoea) and central nervous (headache, dizziness) systems."( An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug.
Alteri, E; Bakshi, R; Gathmann, I; Hermeling-Fritz, I,
)
0.13
" Application of pharmacokinetics permitted definitive treatment with mefloquine in a safe and effective manner."( Coadministration of mefloquine and chloroqine: use of a pharmacokinetic-based approach to reduce toxicity.
Corry, A; Fitzmaurice, L; Jackson, MA; Kearns, GL; Lowry, JA, 2001
)
0.31
" As the use of mefloquine has increased, so have the reports on its adverse effects."( Serious adverse events of mefloquine in relation to blood level and gender.
Almog, S; Potasman, I; Rotenberg, M; Sadetzki, S; Schwartz, E, 2001
)
0.31
" Toxic encephalopathy is a serious neurological manifestation which is slowly reversible depending on individual predisposition."( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine].
Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001
)
0.31
"The frequency and spectrum of adverse events associated with the antimalarial therapeutic regimen of mefloquine (MQ) (750 and 500 mg at an interval of 6 h) was assessed in 22 healthy volunteers who were monitored for 21 days following drug administration."( Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults.
Kollaritsch, H; Mikolasek, A; Noedl, H; Rendi-Wagner, P; Wernsdorfer, WH; Wiedermann, G, 2002
)
0.31
" We critically reviewed 516 published case reports of mefloquine adverse effects, to clarify the phenomenology of the harms associated with mefloquine, and to make recommendations for safer prescribing."( Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?
Croft, AM; Herxheimer, A, 2002
)
0.31
"We postulate that many of the adverse effects of mefloquine are a post-hepatic syndrome caused by primary liver damage."( Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?
Croft, AM; Herxheimer, A, 2002
)
0.31
"Mefloquine's adverse effects need to be investigated through a multicentre cohort study, with small controlled studies testing specific elements of the hypothesis."( Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?
Croft, AM; Herxheimer, A, 2002
)
0.31
"We performed a prospective, double-blind, randomized study to compare the occurrence of neuropsychiatric adverse events and concentration impairment during prophylactic use of either mefloquine or atovaquone plus chloroguanide (INN, proguanil)."( Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.
Ditters, JM; Ligthelm, RJ; Overbosch, D; Stricker, BH; Sturkenboom, MC; van Riemsdijk, MM, 2002
)
0.31
" Severe malaria in rural areas of Sudan, where facilities for the safe and effective use of parenteral quinine are lacking, is a frequent problem."( Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
Alkadru, AM; Awad, MI; Baraka, OZ; Behrens, RH; Eltayeb, IB, 2003
)
0.32
"All drugs used for malaria prophylaxis have common adverse effects, in addition to rare and/or severe adverse effects."( Safety evaluation of the drugs available to prevent malaria.
Beer, MD; Cook, GC; Croft, AM; Whitehouse, DP, 2002
)
0.31
" Groups reporting or not reporting a side effect were similar for gender, age, travel destination, antimalarial prescribed, and elapsed time from clinic visit to telephone contact."( Side effects of and compliance with malaria prophylaxis in children.
Albright, TA; Binns, HJ; Katz, BZ,
)
0.13
" There were no adverse events (AEs) reported during the study."( Randomised efficacy and safety study of two 3-day artesunate rectal capsule/mefloquine regimens versus artesunate alone for uncomplicated malaria in Ecuadorian children.
Cambon, N; Gomez, EA; Jurado, MH, 2003
)
0.32
"Risk factors for mefloquine-associated neuropsychiatric adverse events and concentration impairment are female gender, low BMI, and first-time use."( Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine.
Ditters, JM; Ligthelm, RJ; Overbosch, D; Stricker, BH; Sturkenboom, MC; Tulen, JH; van Riemsdijk, MM, 2004
)
0.32
"The clinical potential of mefloquine has been compromised by reports of adverse neurological effects."( The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains.
Bhattacharjee, AK; Dow, GS; Gerena, L; Hudson, TH; Koenig, ML; Lopez-Sanchez, M; Wolf, L, 2004
)
0.32
" Mefloquine was safe in infants weighing <15 kg in our experience."( Safety of mefloquine in infants with acute falciparum malaria.
Carme, B; Delattre, P; Demar, M; Dubos, F; Gendrel, D, 2004
)
0.32
" There was rapid relief of symptoms the median time of fever clearance was one day and the most common drug related adverse events were headache dizziness and asthenia."( Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya.
Bhatt, KM; Bhatt, SM; Samia, BM; Wasunna, KM, 2006
)
0.33
"Artesunate-mefloquine combination given simultaneously was found to be highly effective and safe in the treatment of uncomplicated malaria."( Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya.
Bhatt, KM; Bhatt, SM; Samia, BM; Wasunna, KM, 2006
)
0.33
"Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"The association between MDR1 C1236T, G2677T, and C3435T single-nucleotide polymorphisms and the occurrence of neuropsychiatric adverse effects was examined in a prospective cohort study of 89 healthy white travelers taking mefloquine."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"Of the subjects, 27 (28%) reported neuropsychiatric adverse effects, women significantly more frequently than men."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"In this study the MDR1 1236TT, 2677TT, and 3435TT genotypes, along with the 1236-2677-3435 TTT haplotype, were associated with neuropsychiatric adverse effects of mefloquine in women."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
" Three (15%) of the 20 atovaquone-proguanil-treated adults had adverse events (AEs), all of which were transient elevations of liver enzymes, while 19 (38%) of the 50 mefloquine-treated adults had AEs, including dizziness in 8 (16%) and nausea/vomiting in 7 (14%)."( Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan.
Hitani, A; Kimura, M; Nakamura, T; Nawa, Y; Ohtomo, H, 2006
)
0.33
" These observations suggest that A/P is also a safe and efficacious drug for the long-term chemoprophylaxis of falciparum malaria."( The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].
Koene, HR; Overbosch, D; Spong, K; van Genderen, PJ,
)
0.13
"To determine adverse events associated with the use of antimalarial chemoprophylaxis in Peace Corps volunteers who have served in malaria-endemic countries 6 months or longer."( Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers.
Bruder, C; Jung, P; Korhonen, C; Peterson, K, 2007
)
0.34
"Survey of Peace Corps volunteers' adverse events associated with the use of antimalarial chemoprophylaxis between August 1, 2005 and July 31, 2006."( Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers.
Bruder, C; Jung, P; Korhonen, C; Peterson, K, 2007
)
0.34
" Nearly two thirds (62%) reported at least one adverse event."( Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers.
Bruder, C; Jung, P; Korhonen, C; Peterson, K, 2007
)
0.34
" In light of the large number of adverse events, having multiple drug regimens available for the long-term traveler may be one method of maintaining adherence to antimalarial chemoprophylaxis."( Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers.
Bruder, C; Jung, P; Korhonen, C; Peterson, K, 2007
)
0.34
" There were no serious adverse events."( Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria.
Agomo, PU; Aina, OO; Ezeiru, VI; Meremikwu, MM; Odey, FA; Oguche, S; Omalu, IJ; Watila, IM, 2008
)
0.35
"This co-packaged formulation of artesunate + mefloquine (Artequin) is highly efficacious, safe and well-tolerated."( Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria.
Agomo, PU; Aina, OO; Ezeiru, VI; Meremikwu, MM; Odey, FA; Oguche, S; Omalu, IJ; Watila, IM, 2008
)
0.35
"A literature review revealed that mefloquine neurotoxicity has been demonstrated at both the preclinical and clinical levels, with nausea, dizziness, sleep disturbances, anxiety and psychosis, amongst other adverse neuropsychiatric events, reported in users."( Mefloquine neurotoxicity: a literature review.
Toovey, S, 2009
)
0.35
" Treatment-related adverse events for the two groups were similar (tafenoquine, 13."( Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010
)
0.36
" Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%)."( Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial.
Adoubryn, KD; Hatz, C; Keiser, J; N'Goran, EK; N'Guessan, NA; Silué, KD; Utzinger, J; Vounatsou, P, 2010
)
0.36
" The most frequent adverse events were vomiting (17%), abdominal pain (11%) and headache (17%)."( Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon.
Agnandji, ST; Bélard, S; Bouyou-Akotet, MK; Heidecker, JL; Issifou, S; Kombila, M; Kremsner, PG; Kurth, F; Mamfoumbi, MM; Mihindou, MP; Missinou, MA; Ngoungou, EB; Ramharter, M; Trapp, S, 2010
)
0.36
" Clinical laboratory electrocardiogram (ECG), adverse events (AEs), efficacy, and pharmacokinetic parameters were assessed over 28 days."( New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Chalermrut, K; Kiechel, JR; Krudsood, S; Leowattana, W; Looareesuwan, S; Navaratnam, V; Olliaro, P; Phumratanaprapin, W; Ramanathan, S; Tangpukdee, N; Taylor, WR; Vaillant, M; Wilairatana, P, 2010
)
0.36
" 50 neurological and neuropsychiatric adverse events occurred in 28 patients."( Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.
Chelo, D; Djoukoue, F; Frey, SG; Hatz, C; Kinkela, MN; Tietche, F; Weber, P, 2010
)
0.36
"African children showed a low percentage of self-limited neurological and neuropsychiatric adverse events, confirming studies on neurological safety in Asian children treated with artesunate and mefloquine."( Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.
Chelo, D; Djoukoue, F; Frey, SG; Hatz, C; Kinkela, MN; Tietche, F; Weber, P, 2010
)
0.36
" We describe an original case of adverse reaction to mefloquine in an overweight patient."( Mefloquine adverse effects with atypical facial lesions in an overweight patient.
Basselin, C; De Monbrison, F; Descloux, E; Peyron, F; Vial, T, 2010
)
0.36
"The causal relationship between mefloquine and the occurrence of these adverse effects is probable."( Mefloquine adverse effects with atypical facial lesions in an overweight patient.
Basselin, C; De Monbrison, F; Descloux, E; Peyron, F; Vial, T, 2010
)
0.36
" Most adverse events were mild or moderate and affected all treatment groups; serious adverse events--vertigo, nausea, vomiting, and anxiety--were reported only by patients taking mefloquine or mefloquine-artesunate."( Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial.
Akkhavong, K; Hatz, C; Keiser, J; Odermatt, P; Sayasone, S; Soukhathammavong, P; Vonghachack, Y; Vounatsou, P, 2011
)
0.37
" However, mefloquine is known to cause adverse neurological and/or psychiatric symptoms, which offset its therapeutic advantage."( Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase.
Aschner, M; Hood, JE; Jenkins, JW; Milatovic, D; Rongzhu, L; Yu, Y, 2011
)
0.37
" The results support the continued safe and efficacious use of artemether-lumefantrine in uncomplicated falciparum malaria."( Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
Barón, C; Carrasquilla, G; Cousin, M; Fisher, LM; Lefèvre, G; Monsell, EM; Sander, O; Walter, V, 2012
)
0.38
" Both DP and A + M were well tolerated, with the majority of adverse events of mild or moderate severity."( Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India.
Bacchieri, A; Bhattacharyya, PC; Corsi, M; Dev, V; Dubashi, N; Gargano, N; Ghosh, SK; Kumar, A; Rao, BH; Srivastava, B; Tommasini, S; Ubben, D; Valecha, N, 2012
)
0.38
" Mefloquine (80 mg/kg bwt/day) was maternally toxic and enhanced fetal variations."( Study on the developmental toxicity of combined artesunate and mefloquine antimalarial drugs on rats.
Boareto, AC; Dalsenter, PR; de Araujo, SL; Gomes, C; Lombardi, N; Lourenço, AC; Lourenço, EL; Minatovicz, B; Müller, JC; Paumgartten, FR, 2012
)
0.38
"Mefloquine use has been linked to severe gastrointestinal and neuropsychiatric adverse effects, including cognitive disturbances, anxiety, depression, psychosis, and violence."( Mefloquine use, psychosis, and violence: a retinoid toxicity hypothesis.
Mawson, A, 2013
)
0.39
" ASMQ was well-tolerated and no serious adverse events were reported."( Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India.
Anvikar, AR; Dash, AP; Dubhashi, NG; Ghosh, SK; Jullien, V; Kiechel, JR; Kumar, A; Rao, BH; Sharma, B; Singh, JP; Srivastava, B; Taylor, WR; Valecha, N, 2013
)
0.39
" No differences were found in the risk of adverse pregnancy outcomes in women exposed to MQ compared to those exposed to other anti-malarials or to the general population."( Mefloquine safety and tolerability in pregnancy: a systematic literature review.
González, R; Greenwood, B; Hellgren, U; Menéndez, C, 2014
)
0.4
" Ideally, the use of MQ to prevent malaria should be based on a risk-benefit analysis of adverse effects against the risk of acquiring the infection."( Mefloquine safety and tolerability in pregnancy: a systematic literature review.
González, R; Greenwood, B; Hellgren, U; Menéndez, C, 2014
)
0.4
" CPS-MQ immunization is safe and equally potent compared to CPS-CQ inducing protection in 7/10 (70%) versus 3/5 (60%) volunteers, respectively."( Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial.
Bastiaens, GJ; Behet, MC; Bijker, EM; Graumans, W; Hermsen, CC; Obiero, JM; Sauerwein, RW; Schats, R; Scholzen, A; Teelen, K; van de Vegte-Bolmer, M; van Gemert, GJ; van Lieshout, L; Visser, LG, 2014
)
0.4
" Serious adverse events (AEs; all causality) were observed more frequently with MQ compared with AZCQ (four vs one, respectively), though discontinuations for AEs were similar (four vs three, respectively)."( Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Chandra, R; Dieng, Y; Djimdé, AA; Dunne, MW; Kain, KC; Mugyenyi, P; Mulenga, M; Oduro, AR; Ogutu, B; Robbins, J; Sagara, I; Sarkar, S; Sie, A; Tiono, AB; Wasunna, M, 2014
)
0.4
" Data indicated that subjects experiencing acute mefloquine adverse side effects may develop long-term mental health problems with a decreased sense of global quality of life with lack of energy, nervousness, and depression."( Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports.
Bech, P; Glenthøj, B; Petersen, E; Ringqvist, Å,
)
0.13
" However, it has been the subject of increased scrutiny and media attention due to its association with significant neuropsychiatric adverse events."( The adverse effects of mefloquine in deployed military personnel.
Adshead, S, 2014
)
0.4
" The primary study objective was to assess the rate of adverse reactions."( The adverse effects of mefloquine in deployed military personnel.
Adshead, S, 2014
)
0.4
"Among a cohort of 111 individuals taking mefloquine, 54% reported at least one adverse effect and 13% required a change in prescription to a second-line anti-malarial, due to significant side-effects."( The adverse effects of mefloquine in deployed military personnel.
Adshead, S, 2014
)
0.4
"There was a higher rate of adverse events reported amongst deployed military personnel than has been reported among civilian patients."( The adverse effects of mefloquine in deployed military personnel.
Adshead, S, 2014
)
0.4
" The majority of visual adverse events were non-serious but 37."( Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis.
Adamcova, M; Bercaru, I; Cockburn, I; Rhein, HG; Schaerer, MT; Schlagenhauf, P,
)
0.13
" Adverse events (AEs) were reported by approximately 30% with both MQ and doxycycline, with 10% discontinuing doxycycline compared with 4% of MQ users."( Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan.
Bennett, K; Garges, E; Kosmowski, AJ; Magill, AJ; Manning, JE; Saunders, DL; Schaffer, S, 2015
)
0.42
"Although mefloquine use is known to be associated with a risk of severe neuropsychiatric adverse reactions that are often preceded by prodromal symptoms, specific combinations of neurologic or psychiatric reactions associated with mefloquine use are not well described in the literature."( Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
Leoutsakos, JM; Nevin, RL, 2017
)
0.46
"Latent class modeling of US Food and Drug Administration Adverse Event Reporting System (FAERS) data was performed using indicators defined by the Medical Dictionary for Regulatory Activities neurologic and psychiatric high-level group terms, in a study dataset of FAERS reports (n = 5332) of reactions to common antimalarial drugs."( Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
Leoutsakos, JM; Nevin, RL, 2017
)
0.46
" Clinical identification of the characteristic symptoms of this syndrome class may aid in improving case finding in pharmacovigilance studies of more serious adverse reactions to the drug."( Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
Leoutsakos, JM; Nevin, RL, 2017
)
0.46
" Here we present the side effect profile of MQ for the treatment of uncomplicated malaria on the Thai-Myanmar/Cambodia borders."( Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017
)
0.46
" Dizziness, nausea, vomiting, headache and asthenia as adverse events (AEs) were more common in MQAS than in AL or DHAPQ (p < 0."( Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.
Buyze, J; D'Alessandro, U; Hachizovu, S; Kabuya, JB; Kasongo, W; Mulenga, J; Mulenga, M; Mwakazanga, D; Nambozi, M; Van Geertruyden, JP, 2017
)
0.46

Pharmacokinetics

Mefloquine is described as a substrate (and possible inhibitor) of CYP3A4. We sought to compare the safety, tolerability and pharmacokinetic profile of (+)-mefloqine with racemic mefloquine.

ExcerptReferenceRelevance
" Pharmacokinetic parameter determination was carried out in 9 cases."( Pharmacokinetics of mefloquine in children aged 6 to 24 months.
Attanath, P; Chongsuphajaisiddhi, T; Djaja Lika, I; Sabcharoen, A; Sheth, UK; Singhasivanon, V; Webster, HK; Wernsdorfer, WH,
)
0.13
"ml-1), as well as a significantly reduced terminal half-life (14."( Effect of tetracycline on mefloquine pharmacokinetics in Thai males.
Back, DJ; Bunnag, D; Karbwang, J; Na Bangchang, K; Rooney, W, 1992
)
0.28
" Other pharmacokinetic parameters appeared to be similar in both groups."( Pharmacokinetics of mefloquine in treatment failure.
Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K; Thanavibul, A, 1991
)
0.28
"The pharmacokinetic properties of mefloquine hydrochloride (15 mg base kg -1) were studied in 12 Karen children (five girls, seven boys) aged between 5 and 10 years presenting with uncomplicated falciparum malaria."( Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria.
Chongsuphajaisiddhi, T; Karbwang, J; Na Bangchang, K; Nosten, F; ter Kuile, F; White, NJ, 1991
)
0.28
" Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14."( Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers.
Bangchang, KN; Bunnag, D; Harinasuta, T; Karbwang, J; Supapojana, A, 1991
)
0.28
" Several assay methodologies have been developed, but high performance liquid chromatography has been the most used in recent pharmacokinetic studies."( Clinical pharmacokinetics of mefloquine.
Karbwang, J; White, NJ, 1990
)
0.28
" The pharmacokinetic parameters for group 1 and group 3 were not significantly different."( Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990
)
0.28
" The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear one-compartment model."( Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet.
Arnold, K; Fu, LC; Guo, XB; Li, GQ; Liu, QD; Wang, NS, 1990
)
0.28
" A dose finding pharmacokinetic study was performed in 20 Karen women in the third trimester of pregnancy receiving antimalarial prophylaxis with mefloquine."( Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.
Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K; Nosten, F; White, NJ, 1990
)
0.28
" However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12."( A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1988
)
0.27
" No significant differences were found between the pharmacokinetic parameters for the OC users and nonOC users."( Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J; Looareesuwan, S; Migasana, S, 1988
)
0.27
" The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear two-compartment model."( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.
Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987
)
0.27
" There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1."( The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1987
)
0.27
" Parameters such as half-life distribution volume, clearance and bioavailability, are defined."( [Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines].
Blayo, MC; Pussard, E; Verdier, F,
)
0.13
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
" Pharmacokinetic studies of mefloquine have been investigated in several groups of subjects either as mefloquine alone or as combined regimens."( Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria.
Karbwang, J; Na-Bangchang, K, 1994
)
0.29
" Similarly, evaluation of the pharmacokinetic properties of halofantrine has led to the demonstration that poor and erratic absorption could be just as likely to explain therapeutic failure as resistance of the parasite to effects of this drug."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data."( Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria.
Bunnag, D; Davis, TM; Karbwang, J; Looareesuwan, S; Na Bangchang, K; White, NJ,
)
0.13
" Mefloquine pharmacokinetic values were comparable to those previously reported by other investigators."( Steady state pharmacokinetics of mefloquine in long-term travellers.
Crevoisier, C; Koren, G; Pennie, RA,
)
0.13
" Some pharmacokinetic implications of the distribution of mefloquine within blood are outlined."( Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications.
Cutler, DJ; Tajerzadeh, H, 1993
)
0.29
" In theory, short half-life compounds reduce the selective pressure for resistance, which may be a major determinant of the useful therapeutic life of an antimalarial drug."( Pharmacology and pharmacokinetics of new antimalarials.
Watkins, WM, 1995
)
0.29
" Pharmacokinetic parameters were calculated using model-independent analysis."( Stereoselective pharmacokinetics of mefloquine in young children.
Attanath, P; Bourahla, A; Chongsuphajaisiddhi, T; Farinotti, R; Gimenez, F; Martin, C; Sabchearon, A; Singhasivanon, V, 1996
)
0.29
" Tmax was also delayed with the combination regimen [14 (5-24) vs 6 (4-16) h]."( Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria.
Banmairuroi, V; Karbwang, J; Molunto, P; Na-Bangchang, K; Thanavibul, A, 1995
)
0.29
" At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1."( Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses.
Crevoisier, C; Farinotti, R; Gimenez, F; Koren, G; Pennie, RA; Wainer, IW, 1994
)
0.29
" A method of repetitive dosing and extending the culture observation period to 28-30 days was used to mimic the in vivo pharmacokinetic situation."( Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics.
Abbas, N; Alin, MH; Björkman, A; Bwijo, B; Wernsdorfer, W, 1997
)
0.3
"60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose."( Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose.
Berggren-Palme, I; Bergqvist, Y; Hellgren, U; Jerling, M, 1997
)
0.3
"Pharmacokinetic and pharmacodynamic interactions between dihydroartemisinin and mefloquine were investigated in 10 healthy Thai males."( Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin.
Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P; Ubalee, R, 1999
)
0.3
"To construct a population pharmacokinetic model for mefloquine in the treatment of falciparum malaria."( Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Aarons, L; Chongsuphajaisiddhi, T; Looareesuwan, S; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; ter Kuile, F; White, NJ, 1999
)
0.3
" The factors that influence the pharmacokinetic properties of mefloquine in acute malaria are not well characterized."( Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Aarons, L; Chongsuphajaisiddhi, T; Looareesuwan, S; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; ter Kuile, F; White, NJ, 1999
)
0.3
"The pharmacokinetic properties of mefloquine were evaluated in 257 patients with acute falciparum malaria by use of nonlinear mixed-effects modeling."( Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Aarons, L; Chongsuphajaisiddhi, T; Looareesuwan, S; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; ter Kuile, F; White, NJ, 1999
)
0.3
"The pharmacokinetic properties of mefloquine in malaria were relatively unaffected by demographic variables (other than body weight) or disease severity."( Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Aarons, L; Chongsuphajaisiddhi, T; Looareesuwan, S; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; ter Kuile, F; White, NJ, 1999
)
0.3
" The pharmacokinetic parameters of mefloquine were estimated using non-compartmental and compartmental analysis."( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria.
Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000
)
0.31
" Mefloquine from the three formulations showed significantly different pharmacokinetic and bioavailability metrics."( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria.
Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000
)
0.31
"Forty-two healthy subjects were randomized in a parallel three-group design trial to investigate potential electrocardiographic and pharmacokinetic interactions between the new antimalarial co-artemether, a combination of artemether and lumefantrine (both of which are predominantly metabolized through CYP3A4), and mefloquine, another antimalarial described as a substrate (and possible inhibitor) of CYP3A4."( Pharmacokinetic interaction trial between co-artemether and mefloquine.
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS, 2000
)
0.31
"This study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between two antimalarial drugs, mefloquine and quinine."( Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine.
Karbwang, J; Na-Bangchang, K; Riengchainam, S; Shrestha, SB; Tan-Ariya, P; Thanavibul, A, 1999
)
0.3
" Mathematical modeling with population pharmacokinetic and in vivo and in vitro pharmacodynamic data from this region confirms that, early in the evolution of resistance, conventional assessments of the therapeutic response ( Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.
Aarons, L; Kyle, DE; Price, RN; Simpson, JA; Watkins, ER; White, NJ, 2000
)
0.31
"The study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between artemether (ARTEM) and quinoline antimalarials namely mefloquine (MQ), quinine (QN) and primaquine (PQ) when given concurrently."( Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.
Karbwang, J; Na-Bangchang, K; Saenglertsilapachai, S; Thanavibul, A; Ubalee, R,
)
0.13
"To evaluate the pharmacokinetic interaction between ritonavir and mefloquine."( Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
Carignan, G; Cooper, C; Gallicano, K; Khaliq, Y; McCarthy, A; Tisdale, C, 2001
)
0.31
"Healthy volunteers participated in two separate, nonfasted, three-treatment, three-period, longitudinal pharmacokinetic studies."( Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
Carignan, G; Cooper, C; Gallicano, K; Khaliq, Y; McCarthy, A; Tisdale, C, 2001
)
0.31
"Study 1: Ritonavir caused less than 7% changes with high precision (90% CIs: -12% to 11%) in overall plasma exposure (AUC(0,168 h)) and peak concentration (Cmax) of mefloquine, its two enantiomers, and carboxylic acid metabolite, and in the metabolite/mefloquine and enantiomeric AUC ratios."( Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
Carignan, G; Cooper, C; Gallicano, K; Khaliq, Y; McCarthy, A; Tisdale, C, 2001
)
0.31
"Information regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug provides the basis for optimizing dosing."( How can we do pharmacokinetic studies in the tropics?
Aarons, L; Simpson, JA; White, NJ,
)
0.13
" Once pharmacokinetic and pharmacodynamic information becomes available, it is possible to use mathematical modelling for testing these protocols and, possibly, for improving them."( Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine.
Ginsburg, HD; Hoshen, MB; Stein, WD, 2001
)
0.31
"No significant pharmacokinetic interactions were observed after co-administration of artemisinin and mefloquine."( Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.
Alin, H; Ashton, M; Bergqvist, Y; Karlsson, MO; Svensson, US, 2002
)
0.31
" Significant changes in the pharmacokinetic parameters of both mefloquine and dihydroartemisinin were observed in patients with malaria compared with healthy subjects reported in a paralleled study."( Pharmacokinetics of the four combination regimens of dihydroartemisinin/mefloquine in acute uncomplicated falciparum malaria.
Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P, 2005
)
0.33
" Since beta-arthemeter is now available, an open-label pharmacodynamic analysis was performed in 73 adults with uncomplicated Plasmodium falciparum malaria."( Pharmacodynamic analysis of antimalarials used in Plasmodium falciparum imported malaria in northern Italy.
Calleri, G; Canta, F; Caramello, P; Cavecchia, I; Di Perri, G; Gobbi, F; Lipani, F; Sergi, G,
)
0.13
" According to the pharmacodynamic parameters measured, no significant differences were recorded among patients with or without prior exposure to malaria."( Pharmacodynamic analysis of antimalarials used in Plasmodium falciparum imported malaria in northern Italy.
Calleri, G; Canta, F; Caramello, P; Cavecchia, I; Di Perri, G; Gobbi, F; Lipani, F; Sergi, G,
)
0.13
" This study was designed to construct a population pharmacokinetic model describing this new dosage regimen of mefloquine given as loose tablets together with artesunate."( Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
Ashley, EA; Hae, R; Hutagalung, R; Lindegårdh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006
)
0.33
" Pharmacokinetic modelling was performed using NONMEM."( Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.
Blomgren, A; Charles, BG; Edstein, MD; Gregory, RM; Harris, IE; Jensen, A; Kitchener, SJ; Nasveld, PE; Reid, MP; Robertson, B, 2007
)
0.34
"5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14."( Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.
Blomgren, A; Charles, BG; Edstein, MD; Gregory, RM; Harris, IE; Jensen, A; Kitchener, SJ; Nasveld, PE; Reid, MP; Robertson, B, 2007
)
0.34
" It was concluded that since no pharmacokinetic drug interaction was observed, MQ dose given 24 hours after an initial dose of DHA is a preferable combination treatment regimen with regard to patient compliance."( Pharmacokinetics of mefloquine with dihydroartemisinin as 2-day regimens in patients with uncomplicated falciparum malaria.
Hung, le N; Hung, NC; Na-Bangchang, K; Thuy, le TD, 2007
)
0.34
"Paediatric drug formulations of artemisinin combination therapies and pharmacokinetic data supporting their use in African children are urgently needed for the effective treatment of young children suffering from falciparum malaria in sub-Saharan Africa."( Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
Adegnika, AA; Agnandji, ST; Bélard, S; Bouyou-Akotet, MK; Cambon, N; Heidecker, JL; Issifou, S; Kombila, M; Kremsner, PG; Kurth, FM; Mamfoumbi, MM; Missinou, MA; Ramharter, M, 2007
)
0.34
"In this study, the pharmacokinetic characteristics of a novel paediatric granule formulation of artesunate-mefloquine therapy were evaluated in comparison to the standard tablet formulation in the treatment of uncomplicated malaria in paediatric patients."( Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
Adegnika, AA; Agnandji, ST; Bélard, S; Bouyou-Akotet, MK; Cambon, N; Heidecker, JL; Issifou, S; Kombila, M; Kremsner, PG; Kurth, FM; Mamfoumbi, MM; Missinou, MA; Ramharter, M, 2007
)
0.34
" This study examines the in vivo efficacy and pharmacokinetic parameters through Day 56 of three commercial formulations of MQ (Lariam, Mephaquin, and Mefloquina-AC Farma) given in combination with artesunate."( Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
Bacon, DJ; Durand, S; Ganguly, B; Green, M; Gutman, J; Quezada, WM; Rojas, OV; Ruebush, TK; Slutsker, L; Utz, GC, 2009
)
0.35
"Whole blood mefloquine concentrations were determined by high-performance liquid chromatography and pharmacokinetic parameters were determined using non-compartmental analysis of concentration versus time data."( Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
Bacon, DJ; Durand, S; Ganguly, B; Green, M; Gutman, J; Quezada, WM; Rojas, OV; Ruebush, TK; Slutsker, L; Utz, GC, 2009
)
0.35
" All three MQ formulations had a terminal half-life of 14-15 days and time to maximum plasma concentration of 45-52 hours."( Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
Bacon, DJ; Durand, S; Ganguly, B; Green, M; Gutman, J; Quezada, WM; Rojas, OV; Ruebush, TK; Slutsker, L; Utz, GC, 2009
)
0.35
" Clinical laboratory electrocardiogram (ECG), adverse events (AEs), efficacy, and pharmacokinetic parameters were assessed over 28 days."( New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Chalermrut, K; Kiechel, JR; Krudsood, S; Leowattana, W; Looareesuwan, S; Navaratnam, V; Olliaro, P; Phumratanaprapin, W; Ramanathan, S; Tangpukdee, N; Taylor, WR; Vaillant, M; Wilairatana, P, 2010
)
0.36
" We sought to compare the safety, tolerability and pharmacokinetic profile of (+)-mefloquine with racemic mefloquine in a randomized, ascending-dose, double-blind, active and placebo-controlled, parallel cohort study in healthy male and female adult volunteers."( A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons.
Bull, F; Duparc, S; Lotharius, J; Möhrle, J; Priestley, A; Tansley, R, 2010
)
0.36
" Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women."( Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Ensom, MH; Wilby, KJ, 2011
)
0.37
"Use of anti-malarial medication in children is hampered by a paucity of dosage, pharmacokinetic and tolerability data."( Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.
Adamcova, M; Bansod, S; Regep, L; Rhein, HG; Schaerer, MT; Schlagenhauf, P, 2011
)
0.37
" The stereoselectivity and pharmacokinetic profile of mefloquine in children is similar to that observed in adults."( Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.
Adamcova, M; Bansod, S; Regep, L; Rhein, HG; Schaerer, MT; Schlagenhauf, P, 2011
)
0.37
" The parasite clearance half-life was calculated from the parasite clearance curve."( Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.
Amaratunga, C; Anderson, JM; Anderson, TJ; Dondorp, AM; Duong, S; Fairhurst, RM; Fay, MP; Jiang, H; Lim, P; Lindegardh, N; Mao, S; Mu, J; Phelps, ES; Song, J; Sreng, S; Stepniewska, K; Su, XZ; Suon, S; White, NJ; Zhou, C, 2012
)
0.38
" The geometric mean half-life was 5·85 h (95% CI 5·54-6·18) in Pursat, similar to that reported in Pailin (p=0·109)."( Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.
Amaratunga, C; Anderson, JM; Anderson, TJ; Dondorp, AM; Duong, S; Fairhurst, RM; Fay, MP; Jiang, H; Lim, P; Lindegardh, N; Mao, S; Mu, J; Phelps, ES; Song, J; Sreng, S; Stepniewska, K; Su, XZ; Suon, S; White, NJ; Zhou, C, 2012
)
0.38
" To accurately identify parasites that are intrinsically susceptible or resistant to artemisinins, future studies should explore the effect of erythrocyte polymorphisms and specific immune responses on half-life variation."( Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.
Amaratunga, C; Anderson, JM; Anderson, TJ; Dondorp, AM; Duong, S; Fairhurst, RM; Fay, MP; Jiang, H; Lim, P; Lindegardh, N; Mao, S; Mu, J; Phelps, ES; Song, J; Sreng, S; Stepniewska, K; Su, XZ; Suon, S; White, NJ; Zhou, C, 2012
)
0.38
" Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM®)."( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013
)
0.39
" From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs' pharmacokinetic profiles."( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013
)
0.39
" The pharmacokinetic analysis was performed using a population approach."( Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
Jullien, V; Kiechel, JR; Sharma, B; Srivastava, B; Valecha, N, 2014
)
0.4
" These values were consistent with the pharmacokinetic results described in Thai patients."( Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
Jullien, V; Kiechel, JR; Sharma, B; Srivastava, B; Valecha, N, 2014
)
0.4
" However, limited data are available on the effect of pregnancy on its pharmacokinetic properties."( Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.
D'Alessandro, U; Davies, GR; Lindegardh, N; Tarning, J; Tinto, H; Toe, LC; Traore-Coulibaly, M; Valea, I; Van Geertruyden, JP; Ward, SA, 2014
)
0.4
" Frequent blood samples were collected before treatment and at scheduled times post-dose for the drug measurements and pharmacokinetic analyses."( Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.
D'Alessandro, U; Davies, GR; Lindegardh, N; Tarning, J; Tinto, H; Toe, LC; Traore-Coulibaly, M; Valea, I; Van Geertruyden, JP; Ward, SA, 2014
)
0.4
" Population pharmacokinetic modelling was conducted using NONMEM."( Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
Evans, AM; Navaratnam, V; Olliaro, PL; Reuter, SE; Upton, RN, 2015
)
0.42
" Monte Carlo simulations predict that falciparum malaria infection is associated with a shorter elimination half-life (407 versus 566 h) and T>MIC (766 versus 893 h)."( Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
Evans, AM; Navaratnam, V; Olliaro, PL; Reuter, SE; Upton, RN, 2015
)
0.42
"This is the first known population pharmacokinetic study to show falciparum malaria to influence mefloquine disposition."( Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
Evans, AM; Navaratnam, V; Olliaro, PL; Reuter, SE; Upton, RN, 2015
)
0.42
"The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect."( Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
Baker, M; Marquart, L; McCarthy, JS; O'Rourke, P, 2015
)
0.42
" The aim of the study was to investigate the pharmacokinetic interaction between the anti-malarial drugs, artesunate-mefloquine and the antiretroviral drug, lopinavir boosted with ritonavir (LPV/r)."( Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.
Cressey, TR; Kongjam, P; Na-Bangchang, K; Rattanapunya, S; Rueangweerayut, R; Tawon, Y, 2015
)
0.42
"The study was an open-label, three-way, sequential, cross-over, pharmacokinetic study in healthy Thai adults."( Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.
Cressey, TR; Kongjam, P; Na-Bangchang, K; Rattanapunya, S; Rueangweerayut, R; Tawon, Y, 2015
)
0.42
" Since mefloquine is being considered as a replacement for sulfadoxine/pyrimethamine in this vulnerable population, an investigation on the pharmacokinetic interactions of mefloquine, sulfamethoxazole and trimethoprim in pregnant, HIV-infected women was performed."( Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya.
Desai, M; González, R; Green, M; Kariuki, S; Katana, A; Menendez, C; Otieno, K; Ouma, P; Slutsker, L; ter Kuile, F, 2016
)
0.43
" Non-compartmental methods using a naïve-pooled data approach were used to determine mefloquine pharmacokinetic parameters."( Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya.
Desai, M; González, R; Green, M; Kariuki, S; Katana, A; Menendez, C; Otieno, K; Ouma, P; Slutsker, L; ter Kuile, F, 2016
)
0.43
" In untreated mice, pRBCs were removed from circulation with a half-life of 15."( Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice.
Akter, J; Aogo, RA; Cromer, D; Davenport, MP; Elliott, T; Fogg, LG; Haque, A; Khoury, DS; Laohamonthonkul, P; Liligeto, UN; Nair, AS; Pernold, CPS; Romanczuk, AS; Soon, MSF; Thomas, BS, 2018
)
0.48
" The present study aimed to develop a population pharmacokinetic model for mefloquine based on whole blood concentration-time profiles of this target population for further dose optimization."( Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border.
Hoglund, RM; Na-Bangchang, K; Ruengweerayut, R, 2018
)
0.48
" A non-linear mixed-effect modelling approach was applied for population pharmacokinetic analysis using the NONMEM v7."( Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border.
Hoglund, RM; Na-Bangchang, K; Ruengweerayut, R, 2018
)
0.48
"Population pharmacokinetic analysis of mefloquine was performed in all patients with a total of 653 samples."( Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border.
Hoglund, RM; Na-Bangchang, K; Ruengweerayut, R, 2018
)
0.48
"To predict the optimal chemoprophylactic dose of mefloquine in infants of 5-10 kg using physiologically based pharmacokinetic (PBPK) and clinical effectiveness models."( Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.
Cleary, Y; Johnson, TN; Parrott, N; Reigner, B; Smith, JR; Toovey, S, 2019
)
0.51
"1 and verified against clinical pharmacokinetic data in adults; the final model, accounting for developmental physiology and enzyme ontogeny was then applied in the paediatric population."( Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.
Cleary, Y; Johnson, TN; Parrott, N; Reigner, B; Smith, JR; Toovey, S, 2019
)
0.51
" This study determined the pharmacokinetic characteristics of the mefloquine stereoisomers and the metabolite carboxymefloquine (CMQ) when given as IPTp in pregnant women."( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.
Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019
)
0.51
"The World Health Organization (WHO) recommends combinations of an artemisinin derivative plus an anti-malarial drug of longer half-life as treatment options for uncomplicated Plasmodium falciparum infections."( Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Aouri, M; Carn, G; Csajka, C; Decosterd, LA; Guidi, M; Kiechel, JR; Mercier, T; Ogutu, B, 2019
)
0.51
"The population pharmacokinetic models developed for both AS/DHA and MQ showed a large variability in drug exposure in the investigated African paediatric population."( Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Aouri, M; Carn, G; Csajka, C; Decosterd, LA; Guidi, M; Kiechel, JR; Mercier, T; Ogutu, B, 2019
)
0.51
" The pharmacokinetic limitation of the current therapy and multi-drug resistance has resulted in an urgent need to study the new antimalarial combinations with existing drugs."( Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using a pH-based precipitation method and its pharmacodynamic properties in a novel artemisinin combination.
Apsingekar, M; Juvekar, S; Kathpalia, H; Mohanraj, K; Shidhaye, S, 2020
)
0.56

Compound-Compound Interactions

A randomized pilot study was conducted in 52 Thai children with uncomplicated multidrug-resistant falciparum malaria. We evaluated three-day treatment with artesunate combined with either 2 or 3 days of mefloquine. Artemisinin derivatives are therefore used in combination with other antimalarials.

ExcerptReferenceRelevance
" Of these 16 new anilides administered orally as one 6 mg/kg dose combined with 18 mg/kg mefloquine hydrochloride, only sulfide 3-arteSanilide 12d was completely curative: on day 30 after infection, all mice in this group had no detectable parasitemia, gained as much weight as the uninfected control mice, and behaved normally."( Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
Girdwood, SC; Mott, BT; Nenortas, E; Posner, GH; Shapiro, TA; Slack, RD; Sullivan, D; Tripathi, A; Triphati, A; Woodard, LE, 2012
)
0.81
" Mefloquine was administered alone (750 mg orally; group 1), or with primaquine (PQ, 45 mg; group 2), or in combination with sulfadoxine (1."( Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990
)
0.28
"Blood induced Plasmodium berghei infection in Swiss mice was exposed during successive passages to melfloquine alone or melfoquine in combination with dapsone or primaquine or erythromycin, and the level of resistance to melfoquine in four sub-lines was compared at ED90 level."( Delay in emergence of mefloquine resistance in Plasmodium berghei by use of drug combinations.
Dutta, GP; Puri, SK, 1989
)
0.28
" 175 Europeans travelling to different malaria endemic areas received either mefloquine alone (250 mg/week) or its combination with sulfadoxine (500 mg/week) plus pyrimethamine (25 mg/week)."( Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria.
Dietrich, M; Horstmann, RD; Reisinger, EC,
)
0.13
"A randomized comparative trial of the pharmacokinetics and pharmacodynamics of oral doses of mefloquine and of mefloquine in combination with artesunate was carried out on 20 Thai male patients with acute, uncomplicated falciparum malaria."( Pharmacokinetics of mefloquine alone or in combination with artesunate.
Back, DJ; Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K; Thanavibul, A, 1994
)
0.29
"A randomized comparative trial of the pharmacokinetics and pharmacodynamics of oral doses of mefloquine and of mefloquine in combination with artesunate was carried out on 20 Thai male patients with acute, uncomplicated falciparum malaria."( Pharmacokinetics of mefloquine alone or in combination with artesunate.
Back, DJ; Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K; Thanavibul, A, 1994
)
0.29
"To compare the therapeutic efficacy of oral artesunate and artemether in combination with mefloquine for the treatment of multidrug resistant malaria, a trial was conducted in 540 adults and children on the Thai-Myanmar border."( Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria.
Brockman, A; Chongsuphajaisiddhi, T; Kham, A; Luxemburger, C; Nosten, F; Price, RN; White, NJ,
)
0.13
" Early disappearance of fever and parasitemia, and absence of important side effects suggest that artesunate, isolated or administrated in combination with mefloquine, constitutes an able therapeutical procedure to constitutes and able therapeutical procedure to contribute for disease control in that region."( [An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of uncomplicated falciparum malaria in an endemic area of Pará, Brazil].
Amoras, WW; Baena, J; Cardoso, Bda S; Crescente, JA; Dourado, HV; Pinheiro, Mda C; Saraty, S,
)
0.13
" The aim of this study was to assess the pharmacokinetics, clinical efficacy and safety of artemisinin alone and in combination with mefloquine."( Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria.
Alin, MH; Ashton, M; Björkman, A; Kihamia, CM; Mtey, GJ, 1996
)
0.29
"A randomized pilot study to compare the safety and efficacy of artesunate suppositories (15 mg/kg/day for three days) versus oral artesunate (6 mg/kg/day for three days), both in combination with mefloquine (25 mg/kg), was conducted in 52 Thai children with uncomplicated multidrug-resistant falciparum malaria."( Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria.
Attanath, P; Brewer, TG; Chanthavanich, P; Chongsuphajaisiddhi, T; Heppner, DG; Mookmanee, D; Phanuaksook, P; Poonpanich, Y; Prarinyanupharb, V; Sabchareon, A; Teja-Isavadharm, P, 1998
)
0.3
" In combination with artesunate, mefloquine administration should be delayed until the second or third day after presentation."( Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.
Chongsuphajaisiddhi, T; Heppner, DG; Luxemburger, C; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; Than, MM; White, NJ, 1999
)
0.3
"A cross sectional study was carried out in a rural area of Myanmar to identify malaria patients' acceptance of artesunate plus mefloquine drug combination and to determine the cost borne by patients."( Acceptance of short course artesunate plus mefloquine drug combination by malaria patients in rural Myanmar.
Aung, S; Lwin, M; Mar, KK; Shwe, T; Win, LL; Zaw, AK, 1999
)
0.3
" The ST provided evidence for the contention that a combination with PQ slowed the selection of resistance to CQ or MEF; it has been shown previously that synergism exists between CQ and either PQ or TAF in rodent malaria."( The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Peters, W; Robinson, BL; Stewart, LB, 2003
)
0.32
" We therefore evaluated three-day treatment with artesunate combined with either 2 or 3 days of mefloquine co-administered once a day with artesunate."( An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria.
Chalermrut, K; Krudsood, S; Leowattana, W; Looareesuwan, S; Silachamroon, U; Srivilairit, S; Tangpukdee, N; Thanachartwet, W; Thimasarn, K; Wilaiaratana, P, 2005
)
0.33
" Our data support the idea that ciprofloxacin in combination with antimalarials may be useful in the treatment of chloroquine-resistant human malaria, allowing the use of lower doses of these drugs."( Enhanced activity of mefloquine and artesunic acid against Plasmodium falciparum in vitro and P. berghei in mice by combination with ciprofloxacin.
Andrade, AA; Boechat, N; de Freitas, IO; de Pilla Varotti, F; de Souza, MV; Krettli, AU; Vasconcelos, TR, 2007
)
0.34
" We evaluated the malaria Sybr green I-based fluorescence (MSF) assay for its use in in vitro drug combination sensitivity assays."( Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.
Co, EM; Dennull, RA; Johnson, JD; Reinbold, DD; Waters, NC, 2009
)
0.35
" Artemisinin derivatives are therefore used in combination with other antimalarials; (4) In 2006, no parasite resistance to artemisinin derivatives has been detected in Southeast Asia after about 10 years of use; (5) In Southeast Asia, parasitological failure at 28 days was less frequent after treatment with artesunate (for 3 days) plus mefloquine than with mefloquine alone."( Artemisinin derivatives and malaria: useful, in combination with other antimalarials.
, 2008
)
0.35
"8 mg/kg of monomeric trioxane 4b combined with 20 mg/kg of mefloquine hydrochloride, all of the malaria-infected mice lived until at least day 30 post infection."( Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose.
Chang, W; Chen, X; Liu, JO; Posner, GH; Shapiro, TA; Woodard, LE, 2009
)
0.35
"The purpose of the study is to explore the efficacy of mefloquine administered orally at single, multiple doses, or in combination with artesuante, artemether, or praziquantel in mouse--Schistosoma japonicum model."( Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum.
Jiao, PY; Mei, JY; Xiao, SH, 2011
)
0.37
" Of these 16 new anilides administered orally as one 6 mg/kg dose combined with 18 mg/kg mefloquine hydrochloride, only sulfide 3-arteSanilide 12d was completely curative: on day 30 after infection, all mice in this group had no detectable parasitemia, gained as much weight as the uninfected control mice, and behaved normally."( Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
Girdwood, SC; Mott, BT; Nenortas, E; Posner, GH; Shapiro, TA; Slack, RD; Sullivan, D; Tripathi, A; Triphati, A; Woodard, LE, 2012
)
0.38
"Forty-six patients in a remote health post of Amazonas, Venezuela, accidentally received artesunate in a dose of 10 mg/kg/day combined with mefloquine."( High dose artesunate in combination with mefloquine: pharmacovigilance in the Venezuelan Amazon.
Brooms, JD; Cruz, L; España, R; Giron, A; Magris, M; Metzger, WG; Peña Pimentel, FN; Perez, L; Villalobos, N; Vivas-Martínez, S, 2012
)
0.38
" There were differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination was administered to mice."( Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.
Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Mosnier, J; Pradines, B; Rogier, C; Savini, H; Soulard, R; Souraud, JB, 2012
)
0.38
" Upon receiving a single oral dose of only 6 mg/kg of the monomeric trioxane 12c combined with 18 mg/kg of mefloquine hydrochloride, Plasmodium berghei-infected mice survived on average 29."( Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose.
Jacobine, AM; Mazzone, JR; Posner, GH; Slack, RD; Sullivan, DJ; Tripathi, AK, 2012
)
0.38
" Following the administration of mefloquine in combination with ART, the patient's neurological status improved substantially."( Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine treatment in combination with antiretroviral therapy in an HIV-infected patient.
Adachi, E; Fujii, T; Imai, K; Iwamoto, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Nakamura, H, 2012
)
0.38
" Apart from hemin, zinc protoporphyrin-IX, and other iron providing agents such as ferrous sulfate and ferriammonium sulfate combined with mefloquine exhibited no toxic effect against schistosomes."( Mefloquine in combination with hemin causes severe damage to adult Schistosoma japonicum in vitro.
Qiao, C; Wang, L; Xiao, SH; Xue, J, 2014
)
0.4
" falciparum in a high-throughput in vitro assay and to protect mice against lethal cerebral malaria caused by Plasmodium berghei ANKA when used alone or in combination with established antimalarial drugs."( Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: antiplasmodial effects and immune responses.
Clark, J; Golenser, J; Guiguemde, WA; Guo, J; Guy, RK; Haynes, RK; Hunt, NH; Marciano, A, 2014
)
0.4
" A revisiting on mefloquine pharmacokinetics-pharmacodynamics (PK/PD) could assist in finding new appropriate dosage regimens in combination with artesunate as a three-day course treatment."( Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria.
Na-Bangchang, K; Saeheng, T, 2023
)
0.91

Bioavailability

Food has been reported to increase the bioavailability of mefloquine in healthy volunteers, but its role in increasing blood me floquine concentrations in malaria patients is unclear. Splitting the 25 mg/kg dose into three doses of 8mg/kg each resulted in improved oral bioavailability compared to conventional split-dose regimen results.

ExcerptReferenceRelevance
" Furthermore, 35 displayed high (78%) rat oral bioavailability with good oral exposure and plasma half-life."( Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
Avery, VM; Charman, SA; Chibale, K; Douelle, F; Duffy, S; Gonzàlez Cabrera, D; Le Manach, C; March, C; Nchinda, AT; Ryan, E; Street, LJ; Taylor, D; Waterson, D; White, KL; Wiesner, L; Wittlin, S; Witty, MJ; Younis, Y, 2014
)
0.4
" These changes in mefloquine disposition after antibiotic treatment may be due both to an increase in fractional bioavailability and a reduction in the enterohepatic recycling of mefloquine."( Effect of ampicillin on mefloquine pharmacokinetics in Thai males.
Back, DJ; Bunnag, D; Karbwang, J; Na Bangchang, K, 1991
)
0.28
"The oral single-dose pharmacokinetics and bioavailability of mefloquine (M) in combination with pyrimethamine (P) and sulfadoxine (S) from a single non-lacquered tablet (NL; M 250 mg, P 25 mg, S 500 mg) and two lacquered tablets (L; M 125 mg, P 12."( Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet.
Arnold, K; Fu, LC; Guo, XB; Li, GQ; Liu, QD; Wang, NS, 1990
)
0.28
" Further studies to determine the oral bioavailability of mefloquine are needed, but these results suggest that clearance may be increased in late pregnancy."( Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.
Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K; Nosten, F; White, NJ, 1990
)
0.28
" Bioavailability of mefloquine suspension in cerebral malaria therefore appears to be adequate for treatment in all but the most severely ill patients."( Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria.
Chanthavanich, P; DiGiovanni, JH; Looareesuwan, S; von Bredow, J; Warrell, DA; Warrell, MJ; White, NJ, 1985
)
0.27
" Exchange of the drug between hemoglobin and the red-cell membrane, however, is fast and may play an important role in the bioavailability of the drug to the parasite."( On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug.
Fabry, ME; Nagel, RL; San George, RC, 1984
)
0.27
" The method, developed in support of bioavailability studies involving the co-administration of different tableted formulations of the drug and an aqueous solution of its 13C3-labeled analog, enables quantification of both dosage forms."( Application of negative-ion chemical ionization isotope dilution gas chromatography--mass spectrometry to single-dose bioavailability studies of mefloquine.
Howald, WN; Kunze, KL; Lawrence, RF; Neal, JM; Trager, WF, 1994
)
0.29
" By comparing the area under the concentration-time curve with that found in a previous study on oral artemisinin, average bioavailability relative to oral administration was estimated to be approximately 30%."( The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria.
de Vries, PJ; Dien, TK; Duc, DD; Kager, PA; Khanh, NX; Koopmans, R; van Boxtel, CJ,
)
0.13
" Delaying administration of mefloquine until day 2 was associated with a mean (95% confidence interval) increase in estimated oral bioavailability of 72% (36 to 109%)."( Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.
Chongsuphajaisiddhi, T; Heppner, DG; Luxemburger, C; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; Than, MM; White, NJ, 1999
)
0.3
" New pharmacokinetic data has shown that food increases the bioavailability of mefloquine."( Mefloquine for malaria chemoprophylaxis 1992-1998: a review.
Schlagenhauf, P, 1999
)
0.3
" Pharmacokinetics of dihydroartemisinin and mefloquine when given concurrently were similar, except for the absorption rate of mefloquine which was faster in the presence of dihydroartemisinin."( Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin.
Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P; Ubalee, R, 1999
)
0.3
" If it is assumed that apparent clearance and volume of distribution are unaffected by dose regimen, then splitting the 25 mg/kg mefloquine dose improves oral bioavailability and the therapeutic response in the treatment of acute falciparum malaria."( Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Aarons, L; Chongsuphajaisiddhi, T; Looareesuwan, S; Nosten, F; Price, R; Simpson, JA; Teja-Isavatharm, P; ter Kuile, F; White, NJ, 1999
)
0.3
" Mefloquine from the three formulations showed significantly different pharmacokinetic and bioavailability metrics."( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria.
Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000
)
0.31
" Lower adherence, higher incidence of adverse effects and reduced bioavailability of doxycycline may have been possible causes."( Malaria during a multinational military deployment: the comparative experience of the Italian, British and Australian Armed Forces in East Timor.
Croft, AM; Kitchener, SJ; Peragallo, MS,
)
0.13
"Food has been reported to increase the bioavailability of mefloquine in healthy volunteers, but its role in increasing blood mefloquine concentrations in malaria patients treated with mefloquine is unclear."( Fatty food does not alter blood mefloquine concentrations in the treatment of falciparum malaria.
Binh, VQ; Dai, B; Dao, NV; Edstein, MD; Ngoa, ND; Quoc, NP; Rieckmann, KH; The, ND; Thuy, le T, 2005
)
0.33
" Splitting the 25 mg/kg dose of mefloquine into three doses of 8 mg/kg each resulted in improved oral bioavailability compared to the conventional split-dose regimen results."( Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
Ashley, EA; Hae, R; Hutagalung, R; Lindegårdh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006
)
0.33
" With these findings the mefloquine loaded Pheroid™ vesicles are stable and should be used investigated for the possible increase in efficacy and bioavailability and decrease toxicity."( Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine.
Kotzé, AF; Plessis, LH; Slabbert, C, 2011
)
0.37
" In-vivo bioavailability studies were conducted in C57 BL6 mice."( Formulation and evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria.
du Plessis, LH; Helena, C; Kotzé, AF; van Huysteen, E; Wiesner, L, 2014
)
0.4
" In-vivo bioavailability study revealed no change in the pharmacokinetic parameters of MQ, and the incorporation of the drug in Pheroid vesicles reduced the in-vitro haemolytic activity by ~75%."( Formulation and evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria.
du Plessis, LH; Helena, C; Kotzé, AF; van Huysteen, E; Wiesner, L, 2014
)
0.4
" The model incorporated population parameter variability for clearance (CL/F), central volume of distribution (VC/F) and absorption rate constant (KA) and identified, in addition to body weight, malaria infection as a covariate for VC/F (but not CL/F)."( Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
Evans, AM; Navaratnam, V; Olliaro, PL; Reuter, SE; Upton, RN, 2015
)
0.42
" Bioavailability of MQ in parasitized RBC lysate was checked in the presence/absence of CLTR using HPLC method."( Clarithromycin enhances the antimalarial efficacy of mefloquine via its increased bioavailability and disrupting P. falciparum apicoplast.
Ahmad, H; Chauhan, BS; Dwivedi, AK; Gunjan, S; Pandey, SK; Singh, SK; Tripathi, R, 2015
)
0.42
" In mice, orally delivered liquid and lyophilized Mef-Lipo displayed comparable absorption with bioavailability (BA) of 81-86%, while the absorption of the standard Mef suspension was significantly lower with BA of 70% and 20% decreased maximal plasma concentration and area under the curve."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46
" In the split-dose group, mefloquine bioavailability was significantly increased by 5%."( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.
Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019
)
0.51

Dosage Studied

The recommended dosage of mefloquine to treat Plasmodium falciparum infection is 25 mg/kg. No recommendation for dosage exceeding 1500 mg. Mefloquine prophylaxis has required a change in its dosing regimen.

ExcerptRelevanceReference
" At this dosage schedule, delayed-type hypersensitivity responses to the same antigen were not affected."( Effect of mefloquine on the immune response in mice.
Ferrante, A; O'Keefe, DE; Rowan-Kelly, B; Thong, YH, 1979
)
0.26
" The proper dosage regimen remains to be defined."( Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria.
Bangchang, KN; Bunnag, D; Chongsuphajaisiddhi, T; Harinasuta, T; Karbwang, J; Thanavibul, A, 1992
)
0.28
" Mefloquine prophylaxis has required a change in its dosing regimen."( Trends and controversies in the prophylaxis and treatment of malaria.
Bia, FJ, 1992
)
0.28
" Mefloquine was shown to be a safe therapeutic agent in the dosage used."( [Clinical experiences with mefloquine in tropical malaria--a prospective study].
Held, T; Mravak, S; Trautmann, M; Weinke, T, 1991
)
0.28
" All mefloquine prophylaxis failures occurred during the second week of the every-2-weeks dosing regimen in volunteers who had used mefloquine for more than 2 months."( Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen.
Bernard, KW; Campbell, CC; Hightower, AW; Lobel, HO; Patchen, LC; Williams, SL, 1991
)
0.28
"Twenty eight adult male patients with acute uncomplicated falciparum malaria which showed RI or RII responses to quinine sulfate at the dosage of 600 mg 8 hourly for 7, 10 or 14 days were treated with a single dose of mefloquine (Lariam); 25 patients received 1000 mg, 2 received 750 mg and 1 received 500 mg."( Quinine resistant falciparum malaria treated with mefloquine.
Bunnag, D; Harinasuta, T; Lasserre, R, 1990
)
0.28
" The dosage of mefloquine is 250 mg weekly (1 tablet Lariam) for 4 weeks, followed by 1 tablet every fortnight."( [Malaria in Switzerland].
Fernex, M, 1988
)
0.27
"8 nmol/l) of PGE2 on the mefloquine- and quinine-induced inhibition of the ACh cumulative dose-response curves were also investigated."( Action of mefloquine on agonist-induced contractions of the guinea-pig isolated ileum.
Go, ML; Lee, HS, 1988
)
0.27
" Six Brazilian volunteers received a loading dose of 2 tablets followed by 20 maintenance doses of 1 tablet at a dosage interval of 7 days."( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.
Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987
)
0.27
" For prophylaxis, it has been suggested that the dosage of 10 mg/kg/wk should be spread over the week (3."( [Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines].
Blayo, MC; Pussard, E; Verdier, F,
)
0.13
" Mefloquine (750 mg) had no significant effect on salivary kinetics of antipyrine or on the metabolic clearance of antipyrine to its three main metabolites, 3-hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine, when antipyrine was administered either 2 h or 2 weeks after dosing with mefloquine."( The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
Back, DJ; Breckenridge, AM; Howells, RE; Rivière, JH, 1985
)
0.27
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
" The incidence of nausea and giddiness was similar in both dosage groups, but the adults in the higher dosage group had a significantly higher frequency of vomiting than those in the low-dose group."( Single-dose treatment of falciparum malaria with mefloquine: field studies with different doses in semi-immune adults and children in Burma.
Hlaing, N; Lasserre, R; Tin, F, 1982
)
0.26
" The clinical and parasitological responses were satisfactory with all three dosage regimens."( A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.
Bunnag, D; Harinasuta, T; Wernsdorfer, WH, 1983
)
0.27
"A sensitive, rapid and selective high-performance liquid chromatographic (HPLC) method has been developed to measure plasma levels of pyrimethamine in human subjects dosed with the antimalarials Fansidar or Fansidar and mefloquine."( Determination of pyrimethamine in human plasma after administration of fansidar of fansidar-mefloquine by means of high-performance liquid chromatography with fluorescence detection.
Timm, U; Weidekamm, E, 1982
)
0.26
" No special dosage adjustments have to be made in patients undergoing hemodialysis treatment to achieve concentrations in plasma similar to those in healthy volunteers."( Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study.
Crevoisier, CA; Fischer, M; Graf, H; Joseph, I, 1995
)
0.29
" The method, developed in support of bioavailability studies involving the co-administration of different tableted formulations of the drug and an aqueous solution of its 13C3-labeled analog, enables quantification of both dosage forms."( Application of negative-ion chemical ionization isotope dilution gas chromatography--mass spectrometry to single-dose bioavailability studies of mefloquine.
Howald, WN; Kunze, KL; Lawrence, RF; Neal, JM; Trager, WF, 1994
)
0.29
"In recent years major advances have been made in the clinical pharmacology of many drugs used for the treatment of tropical diseases, particularly in the design and development of dosage regimens for the treatment of severe malaria."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" In conclusion, pharmacokinetic values determined by this study support mefloquine weekly dosing for long-term malaria chemoprophylaxis; toxic accumulation does not occur and weekly dosing is associated with significantly higher trough levels than 14 d dosing."( Steady state pharmacokinetics of mefloquine in long-term travellers.
Crevoisier, C; Koren, G; Pennie, RA,
)
0.13
" All drug dosing was performed under supervision by the study team, making this an evaluation of intervention efficacy (excluding the role of patient compliance)."( Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi: The Mangochi Malaria Research Project.
Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, WL; Steketee, RW; Wirima, JJ, 1996
)
0.29
" Dose-response studies showed that expression of wild-type pfmdr1 causes cellular resistance to quinine, quinacrine, mefloquine, and halofantrine in yeast cells."( The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells.
Brault, M; Delling, U; Gros, P; Ruetz, S; Schurr, E, 1996
)
0.29
" Subjects kept a daily symptom diary from 2 weeks before until 2 weeks after the dosing period."( Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial.
Batty, KT; Davis, TM; Dembo, LG; Hewitt, BJ; Hislop, RG; Kaye-Eddie, SA, 1996
)
0.29
" Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack."( Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
DeFraites, RF; Kain, KC; Magill, AJ; Smoak, BL; Wellde, BT, 1997
)
0.3
" A method of repetitive dosing and extending the culture observation period to 28-30 days was used to mimic the in vivo pharmacokinetic situation."( Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics.
Abbas, N; Alin, MH; Björkman, A; Bwijo, B; Wernsdorfer, W, 1997
)
0.3
"The MQ enantiomers differ extensively in their disposition both with regard to parameter values and the kinetic stability over time during repeated dosing with racemic MQ."( Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose.
Berggren-Palme, I; Bergqvist, Y; Hellgren, U; Jerling, M, 1997
)
0.3
" In a pilot study carried out in Gabon, a reduced dosage of the triple combination with a mean of 1 mg/kg of mefloquine/2 mg/kg of sulfadoxine/0."( Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone.
Handschin, J; Kremsner, PG; Lehman, LG; Lell, B; Schmidt-Ott, JR; Sturchler, D, 1998
)
0.3
" The rapidity of effect, availability and convenient dosage regimen make artesunate in suppository form a promising treatment for severe falciparum malaria, particularly in rural areas where parenteral formulations are unavailable."( Artesunate suppositories: an effective treatment for severe falciparum malaria in rural areas.
Chongsuphajaisiddhi, T; Looareesuwan, S; Viriyavejakul, P; Wilairatana, P, 1997
)
0.3
" Steady-state pharmacokinetics of weekly prophylaxis in long term travelers have shown that toxic accumulation does not occur and that weekly dosing is associated with protective levels of the drug."( Mefloquine for malaria chemoprophylaxis 1992-1998: a review.
Schlagenhauf, P, 1999
)
0.3
" Mefloquine had borderline bactericidal activity at a dosage of 40 mg/kg daily (100% inhibition compared with a 1-week control), and significant inhibition was obtained at dosages of 40 mg/kg three times a week, as well as 20 mg/kg daily."( Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.
Aralar, PA; Bermudez, LE; Inderlied, CB; Kolonoski, P; Wu, M; Young, LS, 1999
)
0.3
"Single doses (250, 500, 1,000, or 2,000 units/kg) of an ovine polyclonal-specific Fab fragment directed against tumor necrosis factor-alpha (TNF-alpha) were given to 17 adult patients with severe falciparum malaria immediately before treatment with artesunate in a pilot study to assess safety and optimal dosage with a view to future studies."( Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria.
Hills, F; Krudsood, S; Looareesuwan, S; Porter, RS; Sjostrom, L; Warrell, DA; Wilairatana, P, 1999
)
0.3
"Electrocardiograms (ECGs) were recorded before dosing and repeatedly thereafter."( Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers.
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS, 2000
)
0.31
" Further research is needed to determine the best dosage regimen for antimalarial drugs used for chemoprophylaxis in children."( Antimalarial chemoprophylaxis in infants and children.
Kramer, MH; Lobel, HO, 2001
)
0.31
" The latter is defined as regular intake of antimalarial drugs in subtherapeutic dosage in order to suppress the development of clinical disease."( [Malaria--chemoprophylaxis 2001].
Beck, B; Blum, J; Funk, M; Furrer, H; Genton, B; Hatz, FR; Holzer, B; Loutan, L; Markwalder, K; Raeber, PA; Schlagenhauf, P; Siegl, G; Steffen, R; Stürchler, D; Wyss, R, 2001
)
0.31
"We report the case of a patient who did not follow the prescribed dosage and who developed acute neurological disorders after overdosing."( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine].
Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001
)
0.31
" Finally, a table is provided for guiding the optimal choice of dosing intervals under different values of population pharmacokinetics, drug resistance and individual immunity parameters."( Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine.
Ginsburg, HD; Hoshen, MB; Stein, WD, 2001
)
0.31
" The unexpectedly high frequency and severity of adverse reactions after normal therapeutic dosage of MQ in healthy subjects may influence future recommendations regarding the use of MQ for stand-by treatment of suspected malaria in travellers."( Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults.
Kollaritsch, H; Mikolasek, A; Noedl, H; Rendi-Wagner, P; Wernsdorfer, WH; Wiedermann, G, 2002
)
0.31
" Patients were randomized to receive simultaneous dosing (artesunate 200 mg/d plus mefloquine 250 mg/d from the first to the third day [investigational group]) or sequential dosing (artesunate 200 mg/d for 3 d plus mefloquine 250 mg on the second and 500 mg on the third day [reference group])."( A randomized, double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa.
Cambon, N; Kinde-Gazard, D; Kone, M; Massougbodji, A; Mueller, EA; Same-Ekobo, A,
)
0.13
" The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31."( Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
Alkadru, AM; Awad, MI; Baraka, OZ; Behrens, RH; Eltayeb, IB, 2003
)
0.32
" When the cultures were exposed to serial dilutions of anti-malarial drugs, a distinct inhibition of HRP2 production was seen with increasing concentrations of drugs, resulting in sigmoid dose-response curves, similar to those obtained from conventional drug sensitivity assays."( Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II.
Kollaritsch, H; Looareesuwan, S; Miller, RS; Myint, KS; Noedl, H; Sukthana, Y; Wernsdorfer, WH; Wiedermann, G; Wongchotigul, V; Wongsrichanalai, C,
)
0.13
" In the naphtoquine group, thirty patients were prescribed single daily dosage of 1,000 mg for one day."( [A randomized comparative study of naphtoquine, mefloquine and artsunate in the treatment of falciparum malaria].
Chen, RJ; Fu, LC; Guo, WZ; Guo, XB; Ou, FZ; Tan, B; Zheng, QJ, 2003
)
0.32
"Although the average fever-subsidence time and the parasite-clearance time of naphtoquine at single 24-hour dosage of 1,000 mg were longer than those of mefloquine and artesunate, the 28-day curative ratio of naphtoquine was higher than that of mefloquine and artesunate."( [A randomized comparative study of naphtoquine, mefloquine and artsunate in the treatment of falciparum malaria].
Chen, RJ; Fu, LC; Guo, WZ; Guo, XB; Ou, FZ; Tan, B; Zheng, QJ, 2003
)
0.32
" Forty patients demonstrated RI type of response, 37 were cured after being retreated with the same dosage and another 3 patients were cured after the third course of treatment."( Six-years monitoring the efficacy of the combination of artesunate and mefloquine for the treatment of uncomplicated falciparum malaria.
Bunnag, D; Chittamas, S; Kanda, T; Looareesuwan, S; Pornkulprasit, V; Rojanawatsirivej, C; Thimasarn, K; Wattanakoon, Y, 2003
)
0.32
"The current dosage of DP (6."( Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand.
Ashley, EA; Brockman, A; Hutagalung, R; Krudsood, S; Leowattana, W; Looareesuwan, S; McGready, R; Nosten, F; Phaiphun, L; Srivilairit, S; White, NJ; Wilairatana, P, 2004
)
0.32
" The doses and dosing regimens of artesunate and mefloquine varied across trials."( Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria.
Bukirwa, H; Orton, L, 2005
)
0.33
" Plasma mefloquine concentrations were determined 72 h after dosing by using liquid chromatography-mass spectrometry."( Mefloquine induces dose-related neurological effects in a rat model.
Bauman, R; Cabezas, M; Cannard, K; Caridha, D; Dow, G; Du, F; Gomez-Lobo, R; Park, M; Smith, K, 2006
)
0.33
" This study was designed to construct a population pharmacokinetic model describing this new dosage regimen of mefloquine given as loose tablets together with artesunate."( Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
Ashley, EA; Hae, R; Hutagalung, R; Lindegårdh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006
)
0.33
"Convenient once-a-week dosing has made mefloquine a popular choice as malaria prophylaxis for travel to countries with chloroquine-resistant malaria."( Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report.
Browning, J; Dell, ML; Tran, TM, 2006
)
0.33
" Weight had a positive influence on central volume but was insufficient to warrant dosage adjustments."( Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.
Blomgren, A; Charles, BG; Edstein, MD; Gregory, RM; Harris, IE; Jensen, A; Kitchener, SJ; Nasveld, PE; Reid, MP; Robertson, B, 2007
)
0.34
" There are no clear data on whether a higher dosage of rectal artesunate results in a better clinical response."( Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria.
Chaivisuth, A; Chanthavanich, P; Na-Bangchang, K; Pengsaa, K; Pojjaroen-Anant, C; Sabchareon, A; Sirivichayakul, C; Thaiarporn, I; Wisetsing, P, 2007
)
0.34
" There was no definite benefit from increasing the dosage of rectal artesunate from 10 to 20 mg/kg/day."( Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria.
Chaivisuth, A; Chanthavanich, P; Na-Bangchang, K; Pengsaa, K; Pojjaroen-Anant, C; Sabchareon, A; Sirivichayakul, C; Thaiarporn, I; Wisetsing, P, 2007
)
0.34
" In order to resolve this issue, the authors have performed extensive dose-response studies on Panx1-transfected neuroblastoma (Neuro2A) and rat insulinoma (Rin) cells, comparing mefloquine obtained from three suppliers and also comparing the sensitivity to diastereomers."( Mefloquine blockade of Pannexin1 currents: resolution of a conflict.
Iglesias, R; Scemes, E; Spray, DC, 2009
)
0.35
" The patients (n = 25/arm) were treated with (i) two fixed-dose tablets (AS-MQ arm; 100 mg AS-200 mg MQ/tablet) daily for 3 days (days 0, 1, and 2) or (ii) nonfixed AS (AS-plus-MQ arm; 4 mg/kg of body weight/day for 3 days) plus MQ (15 mg/kg on day 1 and 10 mg/kg on day 2), dosed by weight."( New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Chalermrut, K; Kiechel, JR; Krudsood, S; Leowattana, W; Looareesuwan, S; Navaratnam, V; Olliaro, P; Phumratanaprapin, W; Ramanathan, S; Tangpukdee, N; Taylor, WR; Vaillant, M; Wilairatana, P, 2010
)
0.36
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing mefloquine hydrochloride as the only active pharmaceutical ingredient (API) are reviewed."( Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride.
Barends, DM; Dressman, JB; Jantratid, E; Junginger, HE; Kopp, S; Midha, KK; Shah, VP; Stavchansky, S; Strauch, S, 2011
)
0.37
"The recommended dosage of mefloquine to treat Plasmodium falciparum infection is 25 mg/kg, with no recommendation for dosage exceeding 1500 mg."( Mefloquine adverse effects with atypical facial lesions in an overweight patient.
Basselin, C; De Monbrison, F; Descloux, E; Peyron, F; Vial, T, 2010
)
0.36
" Our case emphasizes the difficulties of dosage adaptation in overweight patients."( Mefloquine adverse effects with atypical facial lesions in an overweight patient.
Basselin, C; De Monbrison, F; Descloux, E; Peyron, F; Vial, T, 2010
)
0.36
" However, when the same mefloquine dosage was applied intraperitoneally, the reduction in parasite weight was similar to the reduction seen with oral albendazole application."( In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis.
Hemphill, A; Hermann, C; Keiser, J; Küster, T; Scholl, S; Stadelmann, B, 2011
)
0.37
" We discuss optimal dosing for ABCs and their likely protection against several sexually transmitted and reproductive tract infections."( Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy.
Chandramohan, D; Chico, RM, 2011
)
0.37
"The study objectives to investigate the distribution of the antimalarial drug mefloquine (MQ) in cellular and fluid blood compartments when given at therapeutic dosage with artesunate and to investigate an eventual association with the occurrence of treatment-related adverse events in Thai patients with acute uncomplicated falciparum malaria."( Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate.
Na-Bangchang, K; Ruengweerayut, R; Wernsdorfer, WH, 2011
)
0.37
" Vomiting within 1 hour after dosing occurred in 20% of children."( Mefloquine for uncomplicated Plasmodium falciparum malaria in children.
Minodier, P; Noël, G; Parzy, D; Piarroux, R; Ranque, S; Retornaz, K; Tall, M, 2011
)
0.37
" Early vomiting after mefloquine dosing is frequent, especially in children < 15 kg of weight, but a second dose can be given successfully."( Mefloquine for uncomplicated Plasmodium falciparum malaria in children.
Minodier, P; Noël, G; Parzy, D; Piarroux, R; Ranque, S; Retornaz, K; Tall, M, 2011
)
0.37
" Simultaneously, the feared development of parasite drug resistance might drive dosing increases."( The pharmacogenetics of antimalaria artemisinin combination therapy.
Gil, JP; Piedade, R, 2011
)
0.37
" This reinforces current practice of using weight-based dosage for children."( Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.
Adamcova, M; Bansod, S; Regep, L; Rhein, HG; Schaerer, MT; Schlagenhauf, P, 2011
)
0.37
" The dosing regimen was derived from a study currently underway at Washington University in St."( Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus.
Jett, RA; Moenster, RP, 2012
)
0.38
"The objective of present investigation was to evaluate performance of cocrystals of Mefloquine Hydrochloride (MFL) in tablet dosage form."( Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form.
Murthy, MS; Shete, AS; Yadav, AV, 2013
)
0.39
"Prepared cocrystals of MFL with different ratio of cocrystal formers were incorporated in tablet dosage form and evaluated for micrometric properties, drug content, hardness, disintegration test, vitro dissolution studies and stability studies."( Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form.
Murthy, MS; Shete, AS; Yadav, AV, 2013
)
0.39
"So we can incorporate cocrystals in tablet dosage form to enhance in vitro and in vivo performance."( Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form.
Murthy, MS; Shete, AS; Yadav, AV, 2013
)
0.39
"Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments."( Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
Charman, SA; Gamo-Benito, J; Humberstone, A; Jamsen, KM; McCaw, J; Moehrle, J; Price, RN; Simpson, JA; Smith, K; Zaloumis, S, 2012
)
0.38
" Dosing on body weight appears justified."( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013
)
0.39
" Daily administered FDC ASMQ for three days was dosed by age."( Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia.
Ariey, F; Duong, S; Kiechel, JR; Leang, R; Lim, P; Ménard, D; Navaratnam, V; Ros, S; Taylor, WR, 2013
)
0.39
" This case seems to be attributed to mefloquine resistance, however it is suggested that mefloquine dosage should be modulated by body weight, as is already indicated by some authorities."( Failure of malaria chemoprophylaxis with mefloquine in an oversize traveller to Mozambique.
Angheben, A; Bisoffi, Z; Buonfrate, D; Gobbi, F; Lunardi, G; Rossanese, A, 2013
)
0.39
" In reviewing the literature, mefloquine has had a heterogeneous effect in PML patients, and P-glycoprotein polymorphism and proper dosage could contribute to the various effects seen."( Mefloquine improved progressive multifocal leukoencephalopathy in a patient with immunoglobulin A nephropathy.
Byun, JI; Chu, K; Jung, KH; Lee, SK; Lee, ST; Lim, JA; Moon, J; Park, KI; Shin, JW, 2014
)
0.4
" These options differ by dosing regimen, cost, and side effect profile."( Knowledge, attitudes, and practices regarding antimalarial chemoprophylaxis in U.S. Peace Corps Volunteers--Africa, 2013.
Arguin, PM; Landman, KZ; Tan, KR, 2014
)
0.4
"The determination of dosing regimens for the treatment of malaria is largely empirical and thus a better understanding of the pharmacokinetic/pharmacodynamic properties of antimalarial agents is required to assess the adequacy of current treatment regimens and identify sources of suboptimal dosing that could select for drug-resistant parasites."( Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
Evans, AM; Navaratnam, V; Olliaro, PL; Reuter, SE; Upton, RN, 2015
)
0.42
" The accumulation of further data regarding mefloquine treatment in PML cases may help to elucidate the optimal dosage and time window for effectively treating PML."( Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment.
Ikeda, E; Kanda, T; Kawai, M; Maoka, T; Nakamichi, K; Nakano, Y; Oga, A; Omoto, M; Saijo, M; Sano, H; Sano, Y; Takao, M, 2015
)
0.42
" In particular, the malaria community may be missing the opportunity to dramatically increase ACT effectiveness through regimen changes, particularly through a switch to twice-daily regimens and/or increases in artemisinin dosing levels."( How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?
Hastings, IM; Hodel, EM; Kay, K, 2015
)
0.42
" In a pilot experiment, MEF treatment was applied 5 days per week and was intensified by increasing the dosage stepwise from 12."( Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine that potentially interacts with parasite ferritin and cystatin.
Hemphill, A; Küster, T; Müller, J; Risch, C; Rufener, R; Stadelmann, B, 2015
)
0.42
"Effective progression of candidate antimalarials is dependent on optimal dosing in clinical studies, which is determined by a sound understanding of pharmacokinetics and pharmacodynamics (PK/PD)."( Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.
Angulo-Barturen, I; Baker, M; Duparc, S; Elliott, S; Ferrer, S; Griffin, P; Hooft van Huijsduijnen, R; Jiménez-Díaz, MB; Leroy, D; Marquart, L; Martínez, MS; McCarthy, JS; Möhrle, JJ; O'Rourke, P; Rockett, R; Sekuloski, S; Sloots, T; Trenholme, K; Wells, TN, 2016
)
0.43
" The safety profiles of artesunate-mefloquine and artemether-lumefantrine were similar, with low rates of early vomiting (71 [15·3%] of 463 patients in the artesunate-mefloquine group vs 79 [16·8%] of 471 patients in the artemether-lumefantrine group in any of the three dosing days), few neurological adverse events (ten [2·1%] of 468 vs five [1·1%] of 465), and no detectable psychiatric adverse events."( Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.
Ackermann, I; Aubin, F; Carn, G; Gesase, S; Lusingu, JPA; Mnkande, E; Mrango, Z; Mtoro, A; Ngocho, JS; Ogutu, B; Onyango, KO; Ouedraogo, A; Sirima, SB; Strub, N; Vanraes, J; Yaro, JB, 2016
)
0.43
" The dosage form for Mef is mostly available as adult tablets, and thus children under the age of 5 suffer from poor medication adherence."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46
" The amorphization of ART and MFQ via nano-confinement using mesoporous SBA-15 is a potentially promising approach to enhance the solubility of poorly water-soluble anti-malarial drugs that co-formulated into a single dosage form."( Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15.
Letchmanan, K; Ng, WK; Shen, SC; Tan, RBH, 2017
)
0.46
" In this large clinical study, the pharmacokinetics (PK) of a fixed dose combination of ASMQ was investigated in an African paediatric population to support dosing recommendations used in Southeast Asia and South America."( Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Aouri, M; Carn, G; Csajka, C; Decosterd, LA; Guidi, M; Kiechel, JR; Mercier, T; Ogutu, B, 2019
)
0.51
" The largest contributor to this variability was body weight, which is accommodated for by the ASMQ fixed dose combination (FDC) dosing recommendation."( Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Aouri, M; Carn, G; Csajka, C; Decosterd, LA; Guidi, M; Kiechel, JR; Mercier, T; Ogutu, B, 2019
)
0.51
" The relationship between mg/kg dosage and treatment failures will be assessed using a Cox regression model with study sites considered as a shared frailty term."( The effect of dose on the antimalarial efficacy of artesunate-mefloquine against
Ashley, EA; Dahal, P; Guerin, P; Humphreys, GS; Mansoor, R; Stepniewska, K, 2019
)
0.51
" The proportion of drug bound to plasma protein binding is an important concept when developing drug dosing regimens."( Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats.
Govendir, M; Izes, AM; Kimble, B; Norris, JM, 2020
)
0.56
" Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences."( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021
)
0.62
" Infected mice were dosed with MQ solution or MQ-niosomes at 50 mg/kg/day, starting from the second day post-infection (PI) (acute model) or the fifth week PI (chronic model), and this was continued for six consecutive days."( Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis.
Aboul Asaad, IA; Amer, BS; Carter, WG; El Maghraby, GM; El Sharazly, BM; Ismail, HIH; Mohamed, DA; Yassen, NA, 2023
)
0.91
" A revisiting on mefloquine pharmacokinetics-pharmacodynamics (PK/PD) could assist in finding new appropriate dosage regimens in combination with artesunate as a three-day course treatment."( Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria.
Na-Bangchang, K; Saeheng, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolAn organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency10.75090.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency16.80370.00018.4406100.0000AID720579; AID720580
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency22.38720.354828.065989.1251AID504847
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency31.67680.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency29.24790.005612.367736.1254AID624032; AID624044
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)25.00000.00011.753610.0000AID1899025; AID1899026; AID1899045; AID1899046
Adenosine receptor A2aHomo sapiens (human)Ki6.55300.00001.06099.7920AID331675
Adenosine receptor A1Homo sapiens (human)Ki14.04400.00020.931610.0000AID331674
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)8.80000.00091.901410.0000AID1193564; AID1899020
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki1.90000.00211.840710.0000AID1059571
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)18.00000.00401.966610.0000AID1873204
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (57)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (229)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1602737Protein binding in plasma (unknown origin)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1445943Antispasmodial activity against multidrug-resistant asexual blood stages of Plasmodium falciparum Dd2 after 72 hrs by HRP2-based ELISA2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1440472In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 48 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1210017Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1428723Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication at 10 uM after 24 hrs by RT-PCR method relative to control2017European journal of medicinal chemistry, Feb-15, Volume: 1272,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
AID728700Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as reduction in parasitemia at 30 mg/kg, po measured on day 3 postinfection relative to control2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID664777Antimalarial activity against Plasmodium knowlesi infected in rhesus monkey RBC assessed as [3H]-hypoxanthine incorporation after 12 hrs by scintillation counting2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Sphingolipid analogues inhibit development of malaria parasites.
AID1602734Antibacterial activity against Enterococcus faecalis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1128659Antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as mean survival days at 30 mg/kg, po qd for 4 days2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1254195Antiplasmodial activity against Plasmodium berghei ANKA expressing GFP infected in mouse assessed as reduction of parasitemia level at 30 mg/kg, po qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID1779232Antimalarial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite growth measured after 72 hrs by Monash assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1440476In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 96 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID726919Selectivity ratio of IC50 for Plasmodium falciparum C235 to IC50 for Plasmodium falciparum D62013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
From a cytotoxic agent to the discovery of a novel antimalarial agent.
AID1593288Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1733041Antimalarial activity against ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM assessed as time taken for recrudescence by measuring parasitemia at 1 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1057140Antimalarial activity against drug-sensitive Plasmodium falciparum D6 after 72 hrs by SYBR green I staining-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1593291Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1812460Antiplasmodial activity against Cambodian multidrug-resistant Plasmodium falciparum isolate incubated for 96 hrs measured by SYBR Green 1 assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1254196Antiplasmodial activity against Plasmodium berghei ANKA expressing GFP infected in mouse assessed as means survival days at 30 mg/kg, po qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID1899045Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1899023Metabolic stability in human liver microsomes assessed as intrinsic clearance at 0.5 uM incubated for 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1572686Antimalarial activity against Plasmodium berghei NK65 infected in mouse assessed as reduction in parasite growth at 20 mg/kg, po administered daily for 3 consecutive days and measured on day 7 post parasite inoculation relative to control2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1404703Antiplasmodial activity against ring-stage Plasmodium falciparum 3D7 assessed as reduction in parasite viability after 72 hrs by LDH assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
AID1276214Tmax in Plasmodium chabaudi infected Balb/c mouse plasma at 10 mg/kg, ip by LC-MS/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1224724Inhibition of beta-hematin formation2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives.
AID1276217Drug level in Plasmodium chabaudi infected Balb/c mouse brain at 10 mg/kg, ip at 24 hrs by LC-MS/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID643459Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as decrease in parasitemia at 18 mg/kg, po administered 24 hrs post-infection measured after 3 days by Giemsa microscopy relative to vehicle treated control2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID1378986Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 after 24 hrs by [G-3H]-hypoxanthine incorporation assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID748930Antimalarial activity against Plasmodium berghei str. ANKA infected in po dosed mouse assessed as reduction in parasitemia2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1428722Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication after 24 hrs by RT-PCR method2017European journal of medicinal chemistry, Feb-15, Volume: 1272,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
AID1629460Antimalarial activity against trophozoite stage of Plasmodium falciparum 3D7 infected-erythrocytes assessed as reduction in Leu efflux at 160 nM after 120 mins by UPLC method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1059571Inhibition of human ERG expressed in CHO cells2013ACS medicinal chemistry letters, Nov-14, Volume: 4, Issue:11
Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.
AID1593253Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1150088Binding affinity to sonicated Escherichia coli ColE1 DNA by viscometric titrations1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID1572685Antimalarial activity against Plasmodium berghei NK65 infected in mouse assessed as reduction in parasite growth at 20 mg/kg, po administered daily for 3 consecutive days and measured on day 5 post parasite inoculation relative to control2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1252950Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1629465Antimalarial activity against mefloquine-sensitive Plasmodium falciparum 3D7 infected-erythrocytes assessed as parasite growth inhibition after 48 hrs by sandwich ELISA2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1572687Antimalarial activity against Plasmodium berghei NK65 infected in mouse assessed as reduction in parasite growth at 20 mg/kg, po administered daily for 3 consecutive days and measured on day 9 post parasite inoculation relative to control2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1076163Cytotoxicity against BALB/c mouse splenocytes assessed as [3H]-thymidine incorporation after 24 hrs by beta-radiation counting analysis relative to control2014European journal of medicinal chemistry, Mar-21, Volume: 75Design, synthesis and biological evaluation of 3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propionic acid hydrazones as antiprotozoal agents.
AID1150091Inhibition of Escherichia coli RNA polymerase assessed as reduction in RNA transcription at compound/DNA molar ratio of 11977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID774658Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1162950Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum 3D7 asexual blood stages2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID726921Antimalarial activity against Plasmodium falciparum D6 assessed as growth inhibition after 72 hrs by SYBR Green 1-based fluorescence assay2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
From a cytotoxic agent to the discovery of a novel antimalarial agent.
AID1445942Antispasmodial activity against chloroquine-sensitive asexual blood stages of Plasmodium falciparum 3D7 after 72 hrs by HRP2-based ELISA2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1733034Antimalarial activity against artemisinin-sensitive Plasmodium falciparum F32-TEM by SYBR green dye based fluorescence assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1274373Antimalarial activity against mutidrug resistant Plasmodium falciparum TM91C235 after 48 hrs by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID1899008Antiplasmodial activity against CQ-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth measured after 48 hrs by SYBR Green 1 dye based fluorescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1276201Antimalarial activity against Plasmodium berghei infected in Swiss-Webster mouse assessed as mouse survival upto day 28 at 10 mg/kg qd for 4 days administered via oral gavage2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1140759Resistance index, ratio of IC90 for CQ, MFQ-resistant Plasmodium falciparum TM91C235 clone Southeast asian isolate to IC90 for CQ, MFQ-susceptible Plasmodium falciparum D6 clone Sierra 1/UNC isolate2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID1638537Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1140756Antimalarial activity against CQ-resistant, MFQ-susceptible Plasmodium falciparum W2 clone Indochina 1 isolate assessed as inhibition of parasite proliferation by MSF assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID1276212Drug level in Plasmodium chabaudi infected Balb/c mouse brain treated with 50 mg/kg, ip dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-3''-yl 2-{[2,8-bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidine-1-carboxylate level measured 2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1140757Antimalarial activity against CQ, MFQ-susceptible Plasmodium falciparum D6 clone Sierra 1/UNC isolate assessed as inhibition of parasite proliferation by MSF assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID1440473In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 72 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1276194Antimalarial activity against Plasmodium chabaudi infected in Balb/c mouse assessed as parastemia at 10 mg/kg, ip administered as single dose measured 4 day postinoculation (Rvb = 4.6 +/- 0.5 %)2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1150090Binding affinity to sonicated calf thymus DNA by viscometric titrations1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID1899028Antiplasmodial activity CQ-resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1162949Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID643458Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as decrease in parasitemia at 15 mg/kg, po administered 24 hrs post-infection measured after 3 days by Giemsa microscopy relative to vehicle treated control2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID1445945Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for chloroquine-sensitive asexual blood stages of Plasmodium falciparum 3D72017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1428721Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for Zika virus infected in African green monkey Vero cells2017European journal of medicinal chemistry, Feb-15, Volume: 1272,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
AID1404704Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
AID1593296Inhibition of Plasmodium falciparum cytochrome b-c12019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1252953Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1252955Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1714099Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse model assessed as mean survival days at 30 mg/kg, po qd for 4 consecutive days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID1195271Cytotoxicity against human HepG2A16 cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues.
AID1604203Antiparasitic activity against Plasmodium falciparum D62019European journal of medicinal chemistry, Nov-01, Volume: 181New dimensions in the field of antimalarial research against malaria resurgence.
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1057132Apparent permeability from basolateral to apical side in MDCK cells at 10 uM after 1 hr by LC/MS analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1378993Elimination half life in FVB mouse plasma at 5 mg/kg, iv administered as single dose2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID1162948Gametocytocidal activity against transgenic Plasmodium falciparum NF54-pfs16-GFP late stage gametocytes after 72 hrs by mitotracker red CM-H2XRos dye based confocal imaging assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1572680Cytotoxicity in African green monkey BGM cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1602739Cmax in human2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1276199Ratio of drug level in human blood to plasma2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1899027Antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID728698Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as cured animal at 30 mg/kg, po measured on day 30 postinfection2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1175719Antimalarial activity against chloroquine /mefloquine/pyrimethamine-resistant Plasmodium falciparum C235 by malaria SYBR green 1-based fluorescence (MSF) assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
AID1197872Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po qd for 4 days starting 4 hrs post infection measured on 96 hrs post infection relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID1276196Stability in human plasma after 240 mins by LC/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1903456Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth by SYBR Green-I dye based fluorescence analysis
AID1128650Antimalarial activity against multidrug-resistant Plasmodium falciparum K12014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1558341Antiviral activity against Zika virus MR766 infected in African green monkey Vero cells by plaque assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1140760Resistance index, ratio of IC90 for CQ-resistant, MFQ-susceptible Plasmodium falciparum W2 clone Indochina 1 isolate to IC90 for CQ, MFQ-susceptible Plasmodium falciparum D6 clone Sierra 1/UNC isolate2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID1057137Antimalarial activity against liver stage Plasmodium berghei ANKA sporozoites infected in human HepG2 cells after 48 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1593290Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1873204Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 to 5 mins using [3H]-estrone sulfate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1195270Antimalarial activity against chloroquine and mefloquine-resistant Plasmodium falciparum Dd2 after 48 hrs by SYBR Green I assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues.
AID1899022Metabolic stability in rat liver microsomes assessed as intrinsic clearance at 0.5 uM incubated for 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1143813Antimicrobial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by SYBR Green I assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents--part III.
AID664776Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in O-positive human RBC assessed as [3H]-hypoxanthine incorporation after 48 hrs by scintillation counting2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Sphingolipid analogues inhibit development of malaria parasites.
AID1638536Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1210016Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1076165Antimicrobial activity against erythrocytic stage of chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as [3H]hypoxanthine incorporation after 24 hrs by beta-radiation counting analysis2014European journal of medicinal chemistry, Mar-21, Volume: 75Design, synthesis and biological evaluation of 3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propionic acid hydrazones as antiprotozoal agents.
AID1649916Antimalarial activity against chloroquine-resistant Plasmodium falciparum2019European journal of medicinal chemistry, Mar-15, Volume: 166Triazole derivatives and their antiplasmodial and antimalarial activities.
AID664797Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in O-positive human RBC assessed as [3H]-hypoxanthine incorporation after 48 hrs by scintillation counting in presence of BSA2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Sphingolipid analogues inhibit development of malaria parasites.
AID1853164Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by resazurin dye based fluorescence assay2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID331675Binding affinity to human adenosine A2A receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
AID1638539Antimalarial activity against multidrug-resistant Plasmodium vivax clinical isolates assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1713577Selectivity index, ratio of CC50 for human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by alamar blue assay to IC50 for chloroquine-resistant blood stage Plasmodium falciparum W2 infected in human erythrocytes assessed as parasite2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.
AID1057139Antimalarial activity against drug-resistant Plasmodium falciparum C235 after 72 hrs by SYBR green I staining-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID748931Antiplasmodial activity against erythrocytic stage of multidrug-resistant Plasmodium falciparum W22013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1722046Antimalarial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite growth incubated for 48 hrs2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
In vitro and in vivo evaluation of the antimalarial MMV665831 and structural analogs.
AID1899025Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID774661Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1599414Antiviral activity against DENV2 infected in BHK cells assessed as reduction in viral yield after 24 ro 48 hrs by luciferase reporter gene assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID1602740Elimination half life in human2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1057136Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1378987Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 24 hrs by [G-3H]-hypoxanthine incorporation assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID1719373Antimalarial activity against Plasmodium falciparum 3D7 assessed as reduction in parasitic growth at 16 uM relative to control2021Bioorganic & medicinal chemistry letters, 03-01, Volume: 35Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking.
AID728702Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1150093Binding affinity to calf thymus DNA assessed as melting temperature at 10'-4 M by thermal denaturation assay1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID1713575Antimalarial activity against chloroquine-resistant blood stage Plasmodium falciparum W2 infected in human erythrocytes assessed as parasite growth inhibition incubated for 24 hrs followed by [3H]-hypoxanthine addition and further incubated for 24 hrs fol2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.
AID1140758Antimalarial activity against CQ, MFQ-resistant Plasmodium falciparum TM91C235 clone Southeast asian isolate assessed as inhibition of parasite proliferation by MSF assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID683685Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID748940Half life in human2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1276198Stability in human blood after 240 mins by LC/MS analysis2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID728701Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in mouse at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1572689Antimalarial activity against Plasmodium berghei NK65 infected in mouse assessed as parasite survival at 20 mg/kg, po administered daily for 3 consecutive days (Rvb = 13+/- 3 days)2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID683687Kinetic solubility of the compound at pH 7.42012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID1593287Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1899029Selectivity index, ratio of IC50 for antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 to IC50 for antiplasmodial activity CQ-resistant Plasmodium falciparum W2 by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1899024Metabolic stability in human hepatocytes assessed as intrinsic clearance incubated up to 24 hrs measured per 10^6 cells by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1638538Antimalarial activity against multidrug-resistant Plasmodium falciparum clinical isolates infected assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1899019Apparent permeability across apical to basolateral side in human Caco-2/TC7 cells assessed as drug recovery at 20 uM incubated for 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1733037Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia at 1 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1274371Antimalarial activity against chloroquine-susceptible Plasmodium falciparum D6 after 48 hrs by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID761774Antiplasmodial activity against Plasmodium falciparum K1 after 42 hrs by microdilution method2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Bioactive compounds from the roots of Strophioblachia fimbricalyx.
AID643455Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as host survival at 15 mg/kg, po administered 24 hrs post-infection (Rvb = 6.8 days)2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID1673157Inhibition of cysteine protease in Schistosoma mansoni assessed as reduction in schistosomula viability incubated for 7 days by inverted microscopy analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Highly tunable thiosulfonates as a novel class of cysteine protease inhibitors with anti-parasitic activity against Schistosoma mansoni.
AID1150094Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival time at 80 to 640 mg/kg measured after 60 days post infection relative to control1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID664775Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in O-positive human RBC assessed as [3H]-hypoxanthine incorporation after 48 hrs by scintillation counting2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Sphingolipid analogues inhibit development of malaria parasites.
AID1899020Inhibition of hERG channel expressed in CHO cells at holding potential of -80 mV by whole cell patch clamp method2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1558342Cytotoxicity against BHK21 cells after 24 to 48 hrs by CCK8 assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID331674Binding affinity to human adenosine A1 receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
AID1762619Antimalarial activity against multi drug-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by sci
AID1899046Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analys2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1445952Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po administered at 4, 24, 48, 72 hrs post infection measured on day 4 by Peter's test relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1440474In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as as protection against infection at 100 mg/kg, po single dose administered 72 hrs prior to infection2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1733035Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1629461Antimalarial activity against chloroquine/mefloquine-sensitive Plasmodium falciparum 3D7 infected-erythrocytes assessed as parasite growth inhibition after 48 to 54 hrs by SYBR green 1-based replication method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1440470In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 48 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1894308Inhibition of Beta-hematin assessed as bis-pyridyl-Fe(III)PPIX complex formation incubated for 5 hrs by NP40 detergent-mediated colorimetric assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1227982Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as reduction in parasite growth incubated for 24 hrs by [3H]hypoxanthine incorporation based microculture radioisotope technique based method2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Eremophilane Sesquiterpenes and Diphenyl Thioethers from the Soil Fungus Penicillium copticola PSU-RSPG138.
AID1335799Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected human erythrocytes assessed as reduction in parasite viability after 24 hrs by [3H]-hypoxanthine incorporation assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1197873Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival time at 30 mg/kg, po qd for 4 days starting 4 hrs post infection measured on 96 hrs post infection (Rvb = 4 days)2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID1623305Antiproliferative activity against human U251 cells by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Recent advances in the discovery of small molecules targeting glioblastoma.
AID1276234Antimalarial activity against Plasmodium chabaudi infected in Balb/c mouse assessed as parastemia at 10 mg/kg, ip measured 13 day postinoculation2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID728699Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as survival at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1714098Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse model assessed as reduction in parasitemia at 30 mg/kg, po qd for 4 consecutive days measured at day 7 post infection by flow cytometry analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1057133Half life in mouse plasma at 1 mM by LC/MS analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1871982Antimycobacterial activity against Mycobacterium tuberculosis2022European journal of medicinal chemistry, Feb-05, Volume: 229Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID1602732Antibacterial activity against Staphylococcus aureus2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1162947Antiplasmodial activity against Plasmodium falciparum Dd2 asexual blood stages after 3 days by HRP2 detection based ELISA method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1733036Selective index, ratio of CC50 for African green monkey Vero cells to IC50 for plasmodium falciparum2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1057135Half life in human plasma at 1 mM by LC/MS analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1252951Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1572681Selectivity index, ratio of EC50 for African green monkey BGM cells to IC50 for chloroquine-resistant mefloquine-sensitive Plasmodium falciparum W2 ring stage form infected in human erythrocytes2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1629462Antimalarial activity against chloroquine/mefloquine-sensitive Plasmodium falciparum W2 assessed as parasite growth inhibition by [3H]hypoxanthine incorporation assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1276195Antiplasmodium activity against Plasmodium falciparum W2 by flow cytometry2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1162946Antiplasmodial activity against Plasmodium falciparum 3D7 asexual blood stages after 3 days by HRP2 detection based ELISA method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1057131Efflux ratio of apparent permeability from basolateral to apical side to apical to basolateral side in MDCK cells2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1428725Potency index, ratio of chloroquine EC50 to test compound EC50 for Zika virus infected in African green monkey Vero cells2017European journal of medicinal chemistry, Feb-15, Volume: 1272,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
AID1899007Antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 assessed as inhibition of parasite growth measured after 48 hrs by SYBR Green 1 dye based fluorescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1276204Antimalarial activity against Plasmodium chabaudi infected in Balb/c mouse assessed as parastemia at 10 mg/kg, ip administered as single dose measured 7 day postinoculation (Rvb = 34 +/- 2.3 %)2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1378991Drug uptake in FVB mouse brain at 5 mg/kg, iv administered as single dose by UPLC-MS/MS based equilibrium dialysis method2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID1175718Antimalarial activity against chloroquine-sensitive/mefloquine-resistant Plasmodium falciparum D6 by malaria SYBR green 1-based fluorescence (MSF) assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
AID1899018Apparent permeability across apical to basolateral side in human Caco-2/TC7 cells at 20 uM incubated for 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1755100Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 MRA-102 infected in human O-positive erythrocytes assessed as inhibition of parasite growth at 16 uM2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives.
AID774663Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1276213Drug level in Plasmodium chabaudi infected Balb/c mouse plasma treated with 50 mg/kg, ip dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-3''-yl 2-{[2,8-bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidine-1-carboxylate level measured2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1210015Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1602731Antibacterial activity against Streptococcus pneumoniae2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1752549Antimalarial activity against chloroquine-sensitive plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition measured after 72 hrs by SYBR green dye based fluorescence analysis2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Preparation, biological & cheminformatics-based assessment of N
AID1853165Selectivity index, ratio of IC50 for Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC to IC50 for Cytotoxicity against human HepG2 cells2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID726920Antimalarial activity against Plasmodium falciparum C235 containing mdr1 transporter gene assessed as growth inhibition after 72 hrs by SYBR Green 1-based fluorescence assay2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
From a cytotoxic agent to the discovery of a novel antimalarial agent.
AID1445953Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival time at 30 mg/kg, po administered at 4, 24, 48, 72 hrs post infection by Peter's test (Rvb = 6 to 7 day)2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1673158Inhibition of cysteine protease in Schistosoma mansoni assessed as reduction in schistosomula viability incubated for 3 days by inverted microscopy analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Highly tunable thiosulfonates as a novel class of cysteine protease inhibitors with anti-parasitic activity against Schistosoma mansoni.
AID1602738Volume of distribution in human2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1378992Fraction unbound in FVB mouse brain at 5 mg/kg, iv administered as single dose by UPLC-MS/MS based equilibrium dialysis method2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID1128651Antimalarial activity against drug-sensitive Plasmodium falciparum NF542014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1057138Ratio of IC50 for drug-resistant Plasmodium falciparum C235 to IC50 for drug-sensitive Plasmodium falciparum D62013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1899009Selectivity index, ratio of IC50 for antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 to IC50 for antiplasmodial activity against CQ-resistant Plasmodium falciparum W2 by SYBR Green 1 dye based fluorescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1593289Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID664798Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in O-positive human RBC assessed as [3H]-hypoxanthine incorporation after 48 hrs by scintillation counting in presence of BSA2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Sphingolipid analogues inhibit development of malaria parasites.
AID1209972Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1175717Antimalarial activity against chloroquine-resistant/mefloquine-sensitive Plasmodium falciparum W2 by malaria SYBR green 1-based fluorescence (MSF) assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
AID1899026Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analy2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1572679Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 ring stage form infected in human erythrocytes by spectrophotometric analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
New hybrid trifluoromethylquinolines as antiplasmodium agents.
AID1602733Antibacterial activity against Staphylococcus epidermidis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1649917Antimalarial activity against chloroquine-sensitive Plasmodium falciparum2019European journal of medicinal chemistry, Mar-15, Volume: 166Triazole derivatives and their antiplasmodial and antimalarial activities.
AID1173639Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF542014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis of novel triazole-linked mefloquine derivatives: biological evaluation against Plasmodium falciparum.
AID1274374Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID1579765Antimalarial activity against Plasmodium falciparum asexual blood stage form infected in human assessed as parasite clearance half-life at 10 mg, po after 8 days2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1276200Antimalarial activity against Plasmodium berghei infected in Swiss-Webster mouse assessed as decrease in parasitemia at 10 mg/kg qd for 4 days administered via oral gavage2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria.
AID1143814Antimicrobial activity against chloroquine and mefloquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by SYBR Green I assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents--part III.
AID1252952Cytotoxicity against human A549 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1853163Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID643456Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as host survival at 18 mg/kg, po administered 24 hrs post-infection (Rvb = 6.8 days)2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID1209974Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1440475In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 100 mg/kg, po single dose administered 96 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1713574Antimalarial activity against chloroquine-resistant blood stage Plasmodium falciparum W2 infected in human erythrocytes assessed as parasite growth inhibition at 10 ug/ml incubated for 24 hrs followed by [3H]-hypoxanthine addition and further incubated fo2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.
AID1629463Antimalarial activity against trophozoite stage of Plasmodium falciparum 3D7 infected-erythrocytes assessed as reduction in Leu efflux after 4 hrs by UPLC method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1629464Antimalarial activity against trophozoite stage of Plasmodium falciparum 3D7 infected-erythrocytes assessed as inhibition of Leu efflux at 160 nM after 60 mins by UPLC method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1445944Cytotoxicity against human HepG2 cells by CellTiterGlo assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1252954Cytotoxicity against African green monkey Vero cells after 4 days by GFP detection method2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1440471In vivo antimalarial activity against Plasmodium berghei infected in albino mouse assessed as mouse survival at 30 mg/kg, po single dose administered 24 hrs prior to infection (Rvb = 6 to 7 days)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
AID1150089Binding affinity to sonicated calf thymus DNA at 10'-3 M by spectroscopy1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID1713576Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by alamar blue assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.
AID1128658Antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as reduction of parasitemia at 30 mg/kg, po qd for 4 days2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1899021Metabolic stability in mouse liver microsomes assessed as intrinsic clearance at 0.5 uM incubated for 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1428720Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by XTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 1272,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
AID1254216Antiplasmodial activity against Plasmodium falciparum 3D7 infected in po dosed non-myelodepleted NOD-SCID IL2Rgammanull mouse engrafted with human erythrocytes assessed as reduction of parasitemia level administered qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID1057134Apparent permeability from apical to basolateral side in MDCK cells at 10 uM after 1 hr by LC/MS analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1209973Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1193564Inhibition of human ERG expressed in HEK293 cells assessed as reduction in tail current at membrane potential of +20 mV2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID1315653Antimalarial activity against multi-drug-resistant Plasmodium falciparum K1 by microculture radioisotope technique2016Journal of natural products, 06-24, Volume: 79, Issue:6
Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,039)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990269 (13.19)18.7374
1990's577 (28.30)18.2507
2000's501 (24.57)29.6817
2010's587 (28.79)24.3611
2020's105 (5.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.86 (24.57)
Research Supply Index4.28 (2.92)
Research Growth Index6.54 (4.65)
Search Engine Demand Index126.17 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (74.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials342 (15.46%)5.53%
Reviews14 (19.72%)6.00%
Reviews159 (7.19%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies273 (12.34%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.09%)0.25%
Other57 (80.28%)84.16%
Other1,436 (64.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (56)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Activity of Mefloquine Against Urinary Schistosomiasis [NCT01132248]Phase 265 participants (Actual)Interventional2010-05-31Completed
A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children [NCT03893097]Phase 3726 participants (Actual)Interventional2019-10-14Completed
Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia. [NCT01319448]Phase 1/Phase 2270 participants (Actual)Interventional2011-09-30Completed
Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia [NCT03726593]Phase 4252 participants (Anticipated)Interventional2018-10-04Recruiting
Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon [NCT02084602]Phase 445 participants (Actual)Interventional2014-06-18Completed
A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients [NCT02524444]Phase 1142 participants (Actual)Interventional2015-09-30Completed
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection [NCT01082718]Phase 2/Phase 30 participants (Actual)Interventional2010-03-31Withdrawn(stopped due to Logistical difficulties)
An Open-label Randomised Trial to Assess the Therapeutic Efficacy and Tolerability of Arterolane-piperaquine Plus Single Low Dose Primaquine Versus Arterolane-piperaquine Plus Mefloquine and Single Low Dose Primaquine Versus Artemether-lumefantrine Plus S [NCT03452475]Phase 3219 participants (Actual)Interventional2018-03-07Completed
Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects [NCT02324738]Phase 416 participants (Actual)Interventional2015-01-31Completed
A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge [NCT03698695]Phase 1152 participants (Actual)Interventional2018-09-27Completed
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009. [NCT01144702]Phase 2/Phase 3163 participants (Actual)Interventional2010-11-30Completed
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil [NCT01107145]Phase 416 participants (Actual)Interventional2011-02-28Terminated(stopped due to Extremely slow enrollment)
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria [NCT00852423]Phase 33,428 participants (Actual)Interventional2010-06-30Completed
The Pharmacokinetic of the Fixed-dose Combination of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnant Women [NCT00701961]Phase 2/Phase 348 participants (Actual)Interventional2008-10-31Completed
Safety and Protective Efficacy of Chemoprophylaxis and Sporozoite Immunization With Plasmodium Falciparum NF135 Against Homologous and Heterologous Challenge Infection in Healthy Volunteers in the Netherlands [NCT03813108]43 participants (Actual)Interventional2019-04-01Terminated(stopped due to Subject withdrawals after temporal suspension of the trial (for personal, logistic reasons). At time of reinitiation the number of enrolled subjects did not meet the predefined threshold for continuation of the trial.)
Study to Determine the Efficacy of Artesunate-mefloquine Combination Therapy for the Treatment of Uncomplicated P. Falciparum Malaria in Thailand [NCT02052323]Phase 448 participants (Actual)Interventional2013-10-31Completed
A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil [NCT01082731]Phase 46 participants (Actual)Interventional2010-11-30Terminated(stopped due to Extremely slow enrollment)
An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium F [NCT00444106]Phase 4265 participants (Actual)Interventional2007-05-31Completed
Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy [NCT00811421]5,820 participants (Actual)Interventional2009-09-30Completed
A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar [NCT02792816]550 participants (Actual)Observational2009-06-30Completed
Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine [NCT00970879]Phase 3430 participants (Actual)Interventional2009-12-31Completed
Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations [NCT02653898]Phase 41,050 participants (Actual)Interventional2016-01-31Active, not recruiting
A Phase I Randomised, Double-Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine [NCT00931697]Phase 146 participants (Actual)Interventional2009-06-30Completed
Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western [NCT00936767]Phase 2/Phase 30 participants (Actual)Interventional2010-10-31Withdrawn(stopped due to Did not get approval)
Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial [NCT04847661]Phase 2/Phase 3137 participants (Actual)Interventional2021-03-28Completed
A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Mal [NCT02612545]Phase 1216 participants (Actual)Interventional2015-11-20Completed
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03939104]Phase 31,368 participants (Anticipated)Interventional2021-06-30Recruiting
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03923725]Phase 33,240 participants (Anticipated)Interventional2020-09-01Recruiting
A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa [NCT00978172]Phase 4220 participants (Actual)Interventional2007-12-31Completed
A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML) [NCT00746941]Phase 1/Phase 237 participants (Actual)Interventional2009-01-31Terminated(stopped due to Primary endpoint not achieved)
A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria [NCT00403260]Phase 31,271 participants (Actual)Interventional2007-01-31Completed
Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2) [NCT01939886]Phase 3219 participants (Actual)Interventional2013-04-30Completed
In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya [NCT01976780]Phase 4118 participants (Actual)Interventional2013-06-30Completed
Analysis of Anti-Plasmodium Falciparum Merozoite Surface Protein 1 Antigen Specific Antibodies in a Human Malaria Challenge Using Mefloquine Prophylaxis to Confirm Assay Sensitivity and Establish Key Antibody Kinetic Parameters [NCT00761020]31 participants (Actual)Interventional2008-09-30Completed
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis [NCT01422954]20 participants (Actual)Interventional2012-01-31Completed
Evaluation of the Efficacy and Effectiveness of Combined Therapy With Mefloquine and Artesunate for Uncomplicated Malaria Treatment in the Loreto Region (Amazon Basin), Peru [NCT00164216]208 participants (Actual)Observational2005-03-31Completed
A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy [NCT01054248]Phase 3511 participants (Actual)Interventional2010-02-16Completed
Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs [NCT00158574]Phase 2/Phase 32,419 participants (Actual)Interventional2005-01-31Completed
Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali [NCT00127998]1,011 participants Interventional2005-07-31Completed
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia [NCT00493363]40 participants (Actual)Interventional2007-06-30Completed
The Effect of Malaria on Disease Progression of HIV/AIDS in Kumasi, Ghana [NCT00499876]197 participants (Actual)Interventional2007-10-31Completed
A Phase II/III, Randomized, Double-Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa [NCT00082576]Phase 2/Phase 3238 participants (Actual)Interventional2004-06-30Completed
"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC Farmzashita of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19" [NCT04347031]Phase 2/Phase 3320 participants (Actual)Interventional2020-04-08Completed
Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria [NCT00243737]Phase 270 participants Interventional2005-10-31Completed
Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine [NCT00274235]Phase 31,600 participants (Anticipated)Interventional2005-07-31Completed
Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand [NCT01659281]13 participants (Actual)Interventional2007-09-30Completed
Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia [NCT01708876]Phase 3250 participants (Anticipated)Interventional2012-10-31Completed
A Phase 3, Randomized, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa [NCT00367653]Phase 3397 participants (Actual)Interventional2006-11-30Completed
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]Phase 3300 participants (Actual)Interventional2013-01-31Completed
Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM) [NCT01640587]76 participants (Actual)Interventional2013-11-30Terminated(stopped due to No adequate malaria patient)
Mefloquine Malaria Prophylaxis in HIV-1 Infected Individuals and Its Influence on the Evolution Towards AIDS: a Randomized Placebo-controlled Trial [NCT00373048]300 participants (Anticipated)Interventional2005-10-31Completed
A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea [NCT00322907]Phase 2330 participants Interventional2000-04-30Terminated
Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region [NCT00373607]Phase 3522 participants (Actual)Interventional2003-07-31Completed
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme [NCT01430351]Phase 1144 participants (Anticipated)Interventional2011-09-14Active, not recruiting
A Randomized, Double Blind, Placebo Controlled Evaluation of Weekly Tafenoquine (WR 238605/SB252263) Compared to Mefloquine for Chemosuppression of Plasmodium Falciparum in Western Kenya [NCT02488980]Phase 2306 participants (Actual)Interventional2000-05-31Completed
A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana [NCT02488902]Phase 2521 participants (Actual)Interventional1998-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00403260 (8) [back to overview]Fever Clearance Time
NCT00403260 (8) [back to overview]Parasite Clearance Time
NCT00403260 (8) [back to overview]PCR-corrected ACPR on Day 14
NCT00403260 (8) [back to overview]Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
NCT00403260 (8) [back to overview]Adverse Events and Clinically Significant Laboratory Results
NCT00403260 (8) [back to overview]Crude ACPR on Days 14 and 28
NCT00403260 (8) [back to overview]Fever Clearance at Day 1, 2 and 3
NCT00403260 (8) [back to overview]Parasite Clearance at Day 1, 2 and 3
NCT00444106 (4) [back to overview]Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)
NCT00444106 (4) [back to overview]Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)
NCT00444106 (4) [back to overview]Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42
NCT00444106 (4) [back to overview]Relationship Between Changes in Auditory Function and Treatment Groups
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 in JC Virus (JCV) Load in Cerebrospinal Fluid (CSF)
NCT00746941 (10) [back to overview]Change From Baseline to Week 8 in JC Virus (JCV) Load in Cerebrospinal Fluid (CSF)
NCT00746941 (10) [back to overview]Participants Who Died Within 6 Months
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in Karnofsky Performance Status (KPS) Index Score
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in Participants' Neurological Function Using a Visual Analog Scale (VAS)
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in Symbol Digit Modalities Test (SDMT)
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in T1 Lesion Volume as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in T2 Lesion Volume as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains
NCT00746941 (10) [back to overview]Change From Baseline to Week 4 and Week 8 in the Expanded Disability Status Scale (EDSS) Score
NCT00746941 (10) [back to overview]Participants With Gadolinium (Gd)-Enhanced Lesions at Baseline, Week 4 and Week 8 as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains
NCT02488980 (4) [back to overview]Protective Efficacy Based on Two Consecutive Positive Smears
NCT02488980 (4) [back to overview]Prophylactic Outcome Defined by the Subject Having no Positive Smears
NCT02488980 (4) [back to overview]Safety (SAEs and AEs)
NCT02488980 (4) [back to overview]Time to a Single Positive Smear
NCT03813108 (5) [back to overview]Frequency of Adverse Events After NF135.C10 CPS Immunization
NCT03813108 (5) [back to overview]Time to Parasitemia
NCT03813108 (5) [back to overview]Break Through Infections
NCT03813108 (5) [back to overview]Break Through Infections
NCT03813108 (5) [back to overview]Magnitude of Adverse Events After NF135.C10 CPS Immunization

Fever Clearance Time

Fever clearance time was defined as the time from first dosing to first normal reading of temperature (<37.5°C taken axillary or tympanic; <38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.

Interventionhours (Median)
Pyronaridine - Artesunate15.9
Mefloquine Plus Artesunate16.0

[back to top]

Parasite Clearance Time

Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).

Interventionhours (Median)
Pyronaridine - Artesunate31.7
Mefloquine Plus Artesunate32.0

[back to top]

PCR-corrected ACPR on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Day 14

Interventionpercentage of subjects (Mean)
Pyronaridine - Artesunate99.9
Mefloquine Plus Artesunate99.5

[back to top]

Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00403260)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
Pyronaridine - Artesunate99.2
Mefloquine Plus Artesunate98.1

[back to top]

Adverse Events and Clinically Significant Laboratory Results

Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities (NCT00403260)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life threatenining AENr subj. with ≥1 AE leading to deathNr subj with ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Mefloquine Plus Artesunate190943223044
Pyronaridine - Artesunate3891536024055

[back to top]

Crude ACPR on Days 14 and 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Days 14 and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) on Day 14Cure rate (%) on Day 28
Mefloquine Plus Artesunate99.596.7
Pyronaridine - Artesunate99.998.7

[back to top]

Fever Clearance at Day 1, 2 and 3

Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (<37.5°C axillary/tympanic or <38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Mefloquine Plus Artesunate78.996.298.4
Pyronaridine - Artesunate78.595.999.2

[back to top]

Parasite Clearance at Day 1, 2 and 3

Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (48h after first dose)
Mefloquine Plus Artesunate31.679.890.5
Pyronaridine - Artesunate38.583.891.5

[back to top]

Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)

"To demonstrate the safety of artemether-lumefantrine after 3 days of treatment in patients with acute, uncomplicated falciparum malaria by testing the null hypothesis that the rate of auditory abnormalities is ≥ 15% in the population treated with artemether-lumefantrine as assessed by ABR at Day 7 following initiation of treatment compared with their baseline values. An auditory nerve abnormality is here defined as a greater than 0.30 ms change in Wave III latency from baseline to Day 7. Exact Pearson-Clopper two-sided 95% confidence limits were constructed for all three treatment groups." (NCT00444106)
Timeframe: 7 days

InterventionPercentage of Participants (Number)
Artemether-lumefantrine (Coartem)2.6

[back to top]

Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)

Audiometric measurements such as pure-tone threshold (air conduction tested at 250 to 8000 HZ) day 3, 7, 28 and 42 following initiation of treatment, including changes from baseline. Pure-tone average (PTA) calculated for each ear by averaging the pure-tone threshold values at 500, 1000, 2000 and 3000 HZ. (NCT00444106)
Timeframe: Baseline (Day 1), 3, 7, 28 and Day 42

,,
InterventiondB (Mean)
Baseline Right EarChange from baseline to Day 3 Right EarChange from baseline to Day 7 Right EarChange from baseline to Day 28 Right EarChange from baseline to Day 42 Right EarBaseline Left EarChange from baseline to Day 3 Left EarChange from baseline to Day 7 Left EarChange from baseline to Day 28 Left EarChange from baseline to Day 42 Left Ear
Artemether-lumefantrine12.2-2.5-2.2-2.7-3.011.4-1.2-1.7-2.0-1.5
Artesunate-mefloquine12.7-1.9-2.6-3.6-3.112.5-1.2-1.4-2.5-3.0
Atovaquone-proguanil (Malarone)12.0-2.4-2.6-2.6-3.311.3-1.5-1.3-1.8-2.1

[back to top]

Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42

Percentage of patients with clearance of asexual parasitemia (observed by optical microscopy) within 7 days of initiation of trial treatment without recrudescence within 14, 28 and 42 days respectively after initiation of treatment. Patients with recurrent parasitemia and paired PCR results were classified as either a new infection (different paired genotypes) or a recrudescence (matching paired genotypes). Patients without paired PCR results or ambiguous results were classified as treatment failures. (NCT00444106)
Timeframe: Days 14, 28 and 42

,,
InterventionPercentage of Participants (Number)
Day 14Day 28Day 42
Artemether-lumefantrine (Coartem)99.498.797.5
Artesunate-mefloquine98.198.198.1
Atovaquone-proguanil (Malarone)100.098.198.1

[back to top]

Relationship Between Changes in Auditory Function and Treatment Groups

ABR Wave III latency (ms) changes from baseline to Day 7 in the three drug exposure groups. (NCT00444106)
Timeframe: From Baseline to Day 7

,,
Interventionms (Mean)
Baseline Right EarChange from baseline to Day 7 Right EarBaseline Left EarChange from baseline to Day 7 Left Ear
Artemether-lumefantrine (Coartem)3.860.013.850.01
Artesunate-mefloquine3.86-0.043.82-0.03
Atovaquone-proguanil (Malarone)3.89-0.013.88-0.01

[back to top]

Change From Baseline to Week 4 in JC Virus (JCV) Load in Cerebrospinal Fluid (CSF)

"Change from baseline to Week 4 in JC viral load in CSF is expressed as log10 copies/mL. Negative values indicate a reduction in viral load.~Only participants with measurable baseline values are included. Post-baseline values of 'Below the Limit of Quantification' or 'Below Limit of Detection' or 'Negative' were set to 50. Log10 (50) = 1.699" (NCT00746941)
Timeframe: Day 0 (baseline), Week 4

Interventionlog10 copies/mL (Mean)
Local Standard of Care-0.2424
Local Standard of Care Plus Mefloquine 250 mg-0.0675

[back to top]

Change From Baseline to Week 8 in JC Virus (JCV) Load in Cerebrospinal Fluid (CSF)

"Change from baseline to Week 8 in JC viral load in CSF is expressed as log10 copies/mL. Negative values indicate a reduction in viral load.~Only participants with measurable baseline values are included. Post-baseline values of 'Below the Limit of Quantification' or 'Below Limit of Detection' or 'Negative' were set to 50. Log10 (50) = 1.699" (NCT00746941)
Timeframe: Day 0 (baseline), Week 8

Interventionlog10 copies/mL (Mean)
Local Standard of Care-0.2843
Local Standard of Care Plus Mefloquine 250 mg-0.3455

[back to top]

Participants Who Died Within 6 Months

The death event is counted under the treatment arm relative to adding mefloquine to the treatment regimen. (NCT00746941)
Timeframe: Day 1 up to 6 months

Interventionparticipants (Number)
Local Standard of Care2
Local Standard of Care Plus Mefloquine 250 mg5

[back to top]

Change From Baseline to Week 4 and Week 8 in Karnofsky Performance Status (KPS) Index Score

"The KPS Index classifies participants' functional impairment. KPS can be used to compare effectiveness of different therapies and to assess the prognosis in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the KPS score, the worse the survival for most serious illnesses. The KPS index is subdivided into 3 categories: incapacitated (0 to 40), self-care (50 to 70), and normal activity (80 to 100).~Negative change from baseline scores indicate improved prognosis." (NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionunits on a scale (Mean)
Week 4 (n=12, 21)Week 8 (n=7, 16)
Local Standard of Care0.00-10.0
Local Standard of Care Plus Mefloquine 250 mg-8.10-10.6

[back to top]

Change From Baseline to Week 4 and Week 8 in Participants' Neurological Function Using a Visual Analog Scale (VAS)

"Participants rate their neurological function on a scale of 100 mm line, where the 0 end of the scale indicates poor neurological function and 100 indicates excellent neurological function. VAS was not required for participants who had physical or cognitive impairments that limited their ability to perform the assessment.~Negative change from baseline scores indicates a worsening outcome." (NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionunits on a scale (Mean)
Week 4 (n=9,16)Week 8 (n=4,13)
Local Standard of Care8.926.3
Local Standard of Care Plus Mefloquine 250 mg-0.73.5

[back to top]

Change From Baseline to Week 4 and Week 8 in Symbol Digit Modalities Test (SDMT)

"The SDMT is a simple substitution task. The test gives participants 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0 (worst outcome) to 110 (best outcome).~Negative change from baseline scores indicates a worsening outcome." (NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionunits on a scale (Mean)
Week 4 (n=6,8)Week 8 (n=3,6)
Local Standard of Care4.001.7
Local Standard of Care Plus Mefloquine 250 mg-1.503.8

[back to top]

Change From Baseline to Week 4 and Week 8 in T1 Lesion Volume as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains

(NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionlog10 mm^3 (Mean)
Week 4 (n=12,11)Week 8 (n=5,11)
Local Standard of Care0.14070.0248
Local Standard of Care Plus Mefloquine 250 mg0.16310.1029

[back to top]

Change From Baseline to Week 4 and Week 8 in T2 Lesion Volume as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains

(NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionlog10 mm^3 (Mean)
Week 4 (n=12,11)Week 8 (n=5,10)
Local Standard of Care0.17040.1738
Local Standard of Care Plus Mefloquine 250 mg0.16190.1050

[back to top]

Change From Baseline to Week 4 and Week 8 in the Expanded Disability Status Scale (EDSS) Score

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death) was calculated. Negative change scores indicate improvement. (NCT00746941)
Timeframe: Day 0 (baseline), Week 4 and 8

,
Interventionunits on a scale (Mean)
Week 4 (n=12, 21)Week 8 (n=7, 16)
Local Standard of Care0.790.71
Local Standard of Care Plus Mefloquine 250 mg0.500.88

[back to top]

Participants With Gadolinium (Gd)-Enhanced Lesions at Baseline, Week 4 and Week 8 as Seen on Magnetic Resonance Imaging (MRI) Scans of Participants' Brains

(NCT00746941)
Timeframe: Day 0 (baseline), Week 4, Week 8

,
Interventionparticipants (Number)
Week 0 (n=15,21)Week 4 (n=12,12)Week 8 (n=5,11)
Local Standard of Care851
Local Standard of Care Plus Mefloquine 250 mg887

[back to top]

Protective Efficacy Based on Two Consecutive Positive Smears

Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. Analysis was based on a calculation of protective efficacy (PE) of tefaenoquine, defined as (1-relative risk of developing parasitaemia tafenoquine: placebo) x100% and 95.5% confidence intervals were constructed for the relative risk using Koopman's method. (NCT02488980)
Timeframe: 24 Weeks

InterventionPercentage of Protective Efficacy (Number)
Placebo0
Tafenoquine77.9
Mefloquine56.8

[back to top]

Prophylactic Outcome Defined by the Subject Having no Positive Smears

Prophylactic outcome (success/failure) at the end of the prophylactic treatment phase; outcome was based on absence/presence of asexual stage parasites of any Plasmodium species on a single blood smear. (NCT02488980)
Timeframe: 24 Weeks

,,
Interventionparticipants (Number)
Prophylactic FailureProphylactic Success (total)Prophylactic Success (known)Prophylactic Success (assumed)
Mefloquine92707
Placebo93606
Tafenoquine901266

[back to top]

Safety (SAEs and AEs)

The most commonly reported experiences in subject occurring in at least 20% of subjects in any treatment group. (NCT02488980)
Timeframe: 28 weeks

,,
Interventionparticipants (Number)
At least one AEHeadacheUpper Respiratory Tract InfectionBack PainMyalgiaAbdominal PainCoughingRhinitis
Mefloquine9749261029192920
Placebo9237171225241321
Tafenoquine9845302827252412

[back to top]

Time to a Single Positive Smear

Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. 95.5% confidence intervals were constructed for the relative risk. (NCT02488980)
Timeframe: 24 Weeks

,,
InterventionDays (Median)
First positive smearTwo consecutive positve smears
Mefloquine50165
Placebo4363
Tafenoquine570

[back to top]

Frequency of Adverse Events After NF135.C10 CPS Immunization

The number of adverse events will be recorded by the trial clinicians for all participants. (NCT03813108)
Timeframe: Cohort A: Inclusion until 35 days after challenge infection (35 weeks) Cohort B: Inclusion - premature end of study (22 weeks)

InterventionAdverse events (Number)
1: NF135 CPS-immunization Challenged by NF135139
2: Low Dose NF135 CPS-immunization Challenged by NF135173
3: NF135 CPS-immunization (A/L) Cohort B172

[back to top]

Time to Parasitemia

The effectiveness of CPS-immunization with NF135 sporozoites to protect against malaria challenge infection with homologous N135.C10 or heterologous NF54 sporozoites will be determined by the time to parasitemia in immunized versus non-immunized volunteers after the challenge infection. (NCT03813108)
Timeframe: Day 1 - 28 after malaria challenge infection (28 days)

Interventiondays to parasitaemia (Median)
1: NF135 CPS-immunization Challenged by NF1359
2: Low Dose NF135 CPS-immunization Challenged by NF1357
5: Control Group Challenged by NF135.C10 Cohort A7

[back to top]

Break Through Infections

Number of subjects that required rescue treatment with atovaquone/proguanil due to a positive thick smear in combination with symptoms following NF135.C10 immunizations despite mefloquine prophylaxis (Cohort A) or presumptive artemether/lumefantrine treatment (Cohort B). (NCT03813108)
Timeframe: From day 0 until 28 days after each immunization (28 days)

Interventionparticipants (Number)
Break through following immunization 1
3: NF135 CPS-immunization (A/L) Cohort B2

[back to top]

Break Through Infections

Number of subjects that required rescue treatment with atovaquone/proguanil due to a positive thick smear in combination with symptoms following NF135.C10 immunizations despite mefloquine prophylaxis (Cohort A) or presumptive artemether/lumefantrine treatment (Cohort B). (NCT03813108)
Timeframe: From day 0 until 28 days after each immunization (28 days)

,
Interventionparticipants (Number)
Break through following immunization 1Break through following immunization 2Break through following immunization 3
1: NF135 CPS-immunization Challenged by NF1351034
2: Low Dose NF135 CPS-immunization Challenged by NF1351035

[back to top]

Magnitude of Adverse Events After NF135.C10 CPS Immunization

The severity of adverse events will be recorded (mild/moderate/severe) for each adverse event (NCT03813108)
Timeframe: Cohort A: Inclusion until 35 days after challenge infection (35 weeks) Cohort B: Inclusion - premature end of study (22 weeks)

,,
InterventionAdverse events (Number)
Mild adverse events (grade 1)Moderate adverse events (grade 2)Severe adverse events (grade 3)Serious adverse events (grade 4)
1: NF135 CPS-immunization Challenged by NF13510820110
2: Low Dose NF135 CPS-immunization Challenged by NF13512835100
3: NF135 CPS-immunization (A/L) Cohort B12131191

[back to top]